Questions and Replies

Reply:

1. Currently there are 28 bank branches which provide Home Affairs services.

2. Yes, however there are engagements underway with BASA (Banking Association of South Africa) regarding the expansion of services to more banks.

END

Reply:

The energy generation is still guided by the IRP, relevant policies, and regulatory prescripts.

The National Energy Crisis Committee is a Presidential led initiative which comprises of a number of Ministries including Minister of Electricity, Minister of Mineral Resources and Energy working together to resolve electricity supply challenges through a number of interventions.

Reply:

1. In 1996, the Department of Education assessed the infrastructure at all public schools.  At the time, is was estimated that about 9 000 schools had no appropriate toilets; and were dependent on basic pit toilets.

2. The SANITATION APPROPRIATE FOR EDUCATION (SAFE) Initiative was launched  in 2018.  An assessment was conducted to determine the number of schools dependent on basic pit toilets.  At the time, is was estimated that the number of schools dependent on basic pit toilets has reduced to 3898,  Several of the 3898 schools were small and unviable and were subsequently rationalized and/or closed.  Subsequent to the rationalization and/or closure of small and unviable schools, the SAFE project focused on 3 397; after schools, which were not part of the SAFE original list in 2018 were added. here were also additional schools which were  added to the list..

3. Of these 3 397 SAFE list, the sanitation projects at 2 547 schools have already progressed to practical completion.  The remaining 850 schools have been allocated to implementing agents, and the sanitation protects are scheduled to achieve practical completion during the current fin nail year (2023/24).

Reply:

1. Learner Transport Programme is a shared responsibility between the Department of Basic Education and the Department of Transport. The provisioning of the learner transport programme, is a provincial competency; and the national Departments of Basic Education and Transport, monitor the provisioning of the learner transport programme in provinces.

Province	(a) Number of Learners	(b) Learner Transport Routes	(c ) subsidized by her department
EC	125071	1608	Learner Transport programme is funded through the equitable share allocations to province; and not subsidised by the DBE
FS	9524	397
GP	190857	677
KZN	73933	672
LP	57636	399
MP	69725	524
NC	25878	408
NW	64450	671
WC	64843	566
TOTAL	681917	5922

2. There are no Public Private Partnerships, as the Learner Transport programme is funded through the equitable share allocations to provinces.

Reply:

Find here: Reply

Reply:

(1) Schools are responsible for (a) maintaining and (b) desludging the ventilated improve pit toilets.

(2)  what (a) total number of schools have ventilated improved pit toilets in each province, (b) is the name of each school and (c) number of ventilated improved pit toilets  does each specified school have?

(2)(a)

Province	No. of schools with VIP
EC	2148
FS	71
GP	15
KZN	2639
LP	2353
MP	863
NC	109
NW	174
WC	4
National	8376

(b) and (c) attached Annexure A

Reply:

 

a) There are two management systems being used to monitor projects, namely:

(i) Infrastructure reporting model (IRM) - a monitoring and reporting tool used by provincial departments to report on their infrastructure projects as required by in terms of section 13(1)(e) of the Division of Revenue Act (DoRA).

(ii) The other system being used is the Expanded Public Works Programme Reporting System (EPWP R-S), which is a web based digital is used to report and monitor job creation Key Performance Indicators (KPIs), including job creation data for women, youth and people with disabilities.

b) The Infrastructure Reporting Model (IRM) system are being administered by the National Treasury and the EPWP Reporting System (EPWP R-S) is a system administered by Department of Public Works and Infrastructure.

All the Provincial Departments are charged with the responsibility to report progress on those infrastructure projects via their respective Provincial Treasuries, who monitors progress and verify data quality against the funding allocated. The Sector Departments and National Treasury are responsible for overall monitoring, oversight and quality assurance, this case the Department of Transport for road projects.

Reply:

1. Yes, officials from the Department have been instructed to implement the recommendations from the investigative report. As such, disciplinary proceedings have been initiated.

2. The reasons for the delays were varied. The main reason was that the contract between the Department and Nexia SAB&T had lapsed. This required the Department to enter into a new arrangement with SAB&T to provide expert witness testimony during the disciplinary proceedings.

3. Yes. Misconduct charges were preferred against the official and a disciplinary hearing was convened. The recommendation of the Chairperson was that the charges be withdrawn post the official’s last working day, as the Department lacks jurisdiction to continue to pursue disciplinary proceedings against an official whose employment relationship with the Department has been terminated. Notwithstanding the above, the Department has placed a marker on the payroll system against the official’s termination type, through which the Department will be notified should the official attempt to re-enter the Public Service. This notification will allow the Department the prerogative to invoke Section 16B, subsection (4) of the Public Service Act, 1994 (Proclamation 103 of 1994), as amended, which directs as follows, should it deem expedient:

16B (4) - If an employee of a department (in this subsection referred to as 'the new department'), is alleged to have committed misconduct in a department by whom he or she was employed previously (in paragraph (b) referred to as 'the former department'), the head of the new department-

(a) may institute or continue disciplinary steps against that employee; and

(b) shall institute or continue such steps if so requested-

(i) by the former executive authority if the relevant employee is a head of department; or

(ii) by the head of the former department, in the case of any other employee.

 

END

Reply:

Find here: Reply

Reply:

The Department of Basic Education (DBE) develops the National Catalogue, which lists all Learning and Teaching Support Materials (LTSM); and forward the National Catalogue to Provincial Education Departments (PEDs) for them to procure for their respective schools. These National Catalogue is further uploaded on the DBE website. Subsequently, the DBE develops a Sector Plan for provinces to develop their aligned provincial management plans for procuring learning materials for the ensuing year. The Sector Plan details the activities and time frames to be observed when procuring any learning materials. The sector Plan is attached as reference on when provinces can start with the procurement processes.

(a) (b) (c) and (d) The information requested can be sourced from provinces; as they have their different management plans guided by the Sector Plan.

Reply:

a) The ex-mineworker’s compensation fund programme is the government’s national campaign that tracks, traces and pay former mineworkers' unclaimed benefits, including provident funding and compensation for lung diseases contracted on the job. The Department of Health is responsible for providing compensation benefits to eligible current and ex-mineworkers for occupational lung diseases caused by hazardous exposures in the mines. It also administers the Fund in accordance with the Occupational Diseases of Mines and Works Act, 78 of 1973 which provides for the compensation of occupational injuries or occupational diseases contracted by employees during the course of their employment or death caused by such injuries or illness.

b) 77 403 claims to current and ex-mineworkers or their beneficiaries (if the mineworker is deceased) have been paid as of 27 March 2023 amounting to R2 470 806 271, 00 in South Africa and other countries.

Reply:

(1) With the recent surge in safety problems relating to schools, teachers and pupils, what steps has her department taken to provide support to schools to ensure that schools are a safe space for pupils and teachers

(a) National School Safety Framework

The Department has trained schools on the implementation of the National School Safety Framework (NSSF) which is a guiding framework in addressing all forms of violent incidences in schools including gangsterism. The NSSF empowers schools to identify and manage all safety threats in schools, establish school safety committees comprising of stakeholders such as teachers, police officers, school governing body members and learner representative council members. Furthermore, The NSSF also empowers schools to develop incident reporting mechanisms, establish collaborations with external stakeholders such as the South African Police Service (SAPS), the Department of Social Development and civil society organisations, as well as develop school safety plans and policies to respond to safety challenges.

The Department has further developed a digital training on the NSSF and the Protocol on the Management and Reporting of Sexual Abuse in Schools. The training is accredited by the South African Council of Educators and it is granted 15 CPD points.   A circular to all schools was released late last year, requiring all School Safety Committee members to complete the training.

(b) Monitoring of   School Safety, Sport and Enrichment, Social Cohesion Programmes

The Department conducts annual monitoring of School Safety, Sport and Enrichment, as well as Social Cohesion Programme in 75 districts. The purpose of the Monitoring is to evaluate the level of implementation of school safety programmes in schools by districts and provide the necessary support to strengthen implementation. To date, in the Financial year of 2022-23, seventy-two districts have been monitored.

(c) Protocol to Deal with Incidences of Corporal punishment in schools

The Department developed and published a Protocol to Deal with Incidences of corporal punishment in schools to highlight the abolishment of corporal punishment in schools and to provide provinces, districts and schools guidance on how to deal with issues of corporal punishment. The protocol foregrounds the following areas:

• The steps to be taken by provincial, district, circuit and school SMT in reporting the incidents of corporal punishment in schools.
• The complaints procedures are outlined and the measures to be taken at every level of the system are explicit and include the labour relations processes in response to perpetrators of corporal punishment as well as sexual abuse and harassment.
• In line with the NSSF the Protocol further supports schools in ensuring safe and supportive learning environments that use protective behaviour, positive discipline, restorative justice and positive behaviour intervention support systems.

(d) Protocol on the Management and Reporting of Sexual Abuse and Harassment in Schools

The Department developed and published a Protocol on the Management and Reporting of Sexual Harassment and Abuse in Schools, highlight the illegality of sexual harassment and abuse committed against children in schools, and to provide Provinces, Districts and schools guidance on how to deal with issues of sexual harassment and abuse in schools. The Protocol foregrounds the following:

• The various key legislation that protect children against sexual harassment and abuse which include the Employment of Educators act, 76 of 1998, the South African Council for Educators Act 31 of 2000, the Children’s Act of 2005 and Criminal law (sexual offences and related matters) amendment act, 2007 (act 32 of 2007)
• The steps to be taken by provincial, district, circuit and school SMT in reporting the incidents of sexual abuse and harassment in schools
• The key stakeholders that schools are required to work with in dealing with cases of sexual harassment and abuse in schools

 

(e) Partnership Protocol between the Department of Basic Education and the South African Police Service (SAPS)

The Department also has an established Protocol with SAPS to address crime and violence in schools The Protocol has enabled all schools to be linked to their local police stations, SAPS conduct searches and seizures in schools and conduct crime awareness campaigns in schools. Regularly, schools work with SAPS and local community police forums and social workers to address gangsterism issues. Constantly, searches and seizures of illegal drugs and weapons are done in schools and anti-gangsterism campaigns in collaboration with the Department of Social Development and the Department of Justice and Constitutional Development are conducted in schools.   

(f) Inter-Departmental Campaign on the prevention of Violence, Bullying, Corporal Punishment, Gender-Based Violence, Learner Pregnancy, Drugs and Substance Abuse

The Department and its partner Departments, Social Development, Justice and Constitutional Development, Correctional Services, the South African Police Service and the Department of Communications and Digital Technologies have also embarked on an Inter-Departmental Campaign on Violence Prevention. This Campaign raises awareness on issues such as the prevention of bullying, corporal punishment, gender-based violence, teenage pregnancy and drugs and substance abuse in schools. The Campaign has been championed by the Deputy Minister of Basic Education and is supported by other Deputy Ministers from the partner Departments. The Campaign has been targeting districts with high levels of crime and violence known as hot spots. The Campaign includes build up events that take groups of learners through priority content areas related to violence prevention.

Thus far, the Campaign has been rolled out in five provinces: Gauteng (Gauteng West District), Limpopo (Sekhukhune East District), Mpumalanga (Nkangala District) and the North West (Dr Kenneth Kaunda District), as well as the Eastern Cape (Nelson Mandela Bay).  The Campaign also involves Senior Management Teams, School Governing Bodies, learners, parents and ward councillors of the participating schools, in this way the Campaign is a whole school community engagement. The Department intends to continue rolling out the Campaign in other outstanding provinces during this financial year and into subsequent years.

Moreover, districts in collaboration with provincial education departments and civil society organisations also conduct regular awareness raising interventions that explicit advocate for the prevention of violence in schools.  These provincial led programmes include school assembly talks, public debates and dialogues amongst learners.  The DBE monitors these awareness programmes through the District Monitoring of School Safety Programmes annually.

(g) Code of Conducts and Policies

The Department compels all schools to develop and adopt code of conducts to address ill-discipline behaviour of learners. School code of conducts are aligned with the Constitution of South Africa and child-protection legislation; and are communicated and adopted/ agreed to by all school stakeholders such as Senior Management Teams, School Governing Bodies and Learner Representative Councils. School codes of conduct are further supplemented by anti-bullying policies, alcohol and drug abuse policies which contribute towards creating safe and enabling environments in schools. 

(h) Disaster Risk Assessment Tool

The Department has collaborated with SANTAM in developing a disaster risk management tool. The tool enables schools to identify disaster risk challenges and develop alternatives to those challenges. Currently, the Department is primarily focusing on rolling it out in special schools across the country. To date, the tool was piloted in Limpopo and Free State Provinces. Furthermore, Mpumalanga has also been trained on the tool.

 

(2) Whether there are any long-term interventions that her department is planning to implement to ensure a secure and safe schooling environment; if not, why not; if so, what interventions?   

(a) National School Safety Framework (NSSF)

The Department plans to collaborate with Provincial Education Departments to promote the digital training on the NSSF and Protocol on the Management and Reporting of Sexual Abuse in Schools. The aim is to ensure that a high number of school safety committee members undertake the training and implement it in their respective schools. The Department will further provide additional physical training to some district officials across various provinces, with an aim to strengthen implementation of the NSSF at school level.

(b) Partnership Protocol between the Department of Basic Education and the South African Police Service (SAPS)

The Department intends to work with the South African Police Service and undertake a review of the Protocol. The aim is to identify the weaknesses of the current protocol and develop solutions to strengthen implementation. In the meantime, activities pertaining to the protocol such as searches and seizes will continue to happen in schools.

Reply:

 

a) The Tender for the Appointment of the Engineering, Procurement and Contract Management (EPMC) contractor is currently at the Bid Adjudication Stage. The item will be subjected to PRASA Board of Control for approval.

b) The complexity of the technical requirements of the bid resulted in bidders requesting an extension to the closing date of the tender.

Reply:

The Department of Basic Education (DBE), in collaboration with a team of reading experts from civil society organisations, academia, Provincial Education Departments (PEDs), and schools, developed the Integrated National Reading Sector Plan (hereafter referred to as the Sector Plan). The Sector Plan recognises that sustainable improvements in reading, require a comprehensive response that involves more than classroom interventions. It therefore, provides a framework for promoting reading and improving literacy levels by focusing on a number of pillars; for example, teacher development and support; strengthening classroom practices; building the capacity of the sector to monitor and support reading development; parental and community support and mobilisation; partnerships; etc. Using this framework, Provincial Education Departments (PEDs) developed more localised plans.

The DBE, supported by the National Education Collaboration Trust (NECT), has however been reflecting on the implementation of the Sector Plan. This reflection process includes assessing the Sector Plan, to determine its strengths and weaknesses, with a view to strengthening it. To this end, a Steering Committee has been set up to oversee this work.  Experts from the sector, will be brought in to support the steering committee. It is envisaged that at the end of this process, the DBE will have a revised and strengthened Integrated National Reading Sector Plan.

Reply:

a(i). The department has assigned some of its resources to areas that were inaccessible, the work is being done using available resources. This means that some of the plans had to be put on hold to attend to some of these emergencies brought by flood damages.

ii) There are some bridges that have been included in the bridge programme where ECDOT is working with National Department of Public Works and Infrastructure. Confirmation for implementation will only be determined once Department of Défense has conducted assessment for suitability or feasibility.

b. ECDOT is mandated with maintenance and construction of provincially proclaimed roads. ECDOT always strives to improves delivery it is mandated with, using the available resources. Partnership with NDPWI and Department of Defence is one of other possible ways in which ECDOT is trying to avoid loss of lives.

Reply:

The interim relief that was implemented by the Government through the sale of strategic stocks cushioned the pump prices by R1,50 per litre during the months of April and May 2022. The South African consumers could have paid R1,50 per litre more for petrol and diesel during the same period if the relief was not there.

Reply:

The Department of Basic Education (DBE) is leading a public discourse through dialogues and engagements in partnership with internal stakeholders, relevant Government Departments, Civil Society Organisations (CSOs), Development Agencies and other types of implementing partners to address violation of human rights and socio-educational inclusion of children with diverse Sexual Orientation, Gender Identity, Expression and Sex Characteristics (SOGIESC) in Schools. This engagement effort has been initiated to enrich the ongoing consultations on the Draft Guidelines for the Socio-educational Inclusion of Diverse SOGIESC in Schools. 

It is expected that the ongoing consultations will give direction to the sector regarding the necessary adaptations in basic education practice, to afford an opportunity for learners with diverse sexual and gender identities to participate in, among others, school sport and co-curricular programmes without discrimination, prejudice and related intolerance. 

The adaptations are going to unfold incrementally over a period. Already, in the South African Schools Choral Eisteddfod (SASCE), we have progressed in addressing school choir gender binary of male and female voices, to refer to the choirs as Soprano, Alto, Tenor and Bass voices, with their related voice variations. This will afford the learner with diverse sexual and gender identity an opportunity to participate in any voice category of their choice. 

In respect of Sport, the process will require a more in depth engagement with the South African Sports Confederation and Olympic Committee (SASCOC) and the various National Sports Federations and the School Sport fraternity, because we are aware that the different game rules are guided by International Federation standards, which already come with compulsory heteronormative gender prescriptions. So, the DBE is unable to detangle these sports adaptations unilaterally, without the consideration of the international and national sports contexts. A confluence of ideas will be required to guide the sector in this exercise. 

In the meantime, as we continue to promote social cohesion and nation building through the Interdepartmental Bullying Prevention Campaign Roadshows, we include Homophobic Bullying as a prominent theme, to send out a strong message by the sector against bullying of learners with diverse sexual and gender identities and promote a school ethos of constitutional values, peace-building and tolerance. 

Reply:

1. The bridge in question may be one of the bridges on the unproclaimed roads, meaning that it is neither registered on the provincial road asset nor municipal road asset.

Since the recent floods, the Mpumalanga provincial government embarked on a programme to conduct an assessment to determine the extent of damage to infrastructure in the area of Bushbuckridge.

As a response to the damages caused by floods, the province and municipality agreed on a joint programme through a municipal support programme whereby a monthly activity such as grading, backfill and re-gravel are being undertaken on the affected roads.

With regard to the affected bridge, the province will be finalising the road and bridge condition assessment which will guide the type of intervention, budget and estimated timelines required.

2. The Department does not have a budget specifically allocated for this bridge, however the province has put aside a budget of R16 million for the maintenance of all bridges across the province.

Reply:

Find here: Reply

Reply:

Operationally, the National Joints Operations (NATJOINTS) structure, which is chaired by the South African Police Services (SAPS), is responsible to coordinate the preventative and responsive actions of the justice and security cluster. The Department, through its Immigration Inspectorate, is represented in the NATJOINTS and participates in the joint operations that are conducted by law enforcement agencies to deal with crime countrywide. These operations are intelligence-driven.

The Department is also part of the National Intelligence Co-ordinating (NICOC) structure, where high security risks cases are identified and the investigation and prosecution thereof are planned and authorised for implementation. As and when illegal activities are detected, such as money laundering and the funding of terrorist organisations by foreign nationals as referred to, the information is shared at the structure and investigated within the shortest possible time.

The prevention of illicit financial flows and money laundering will be handled by the Financial Intelligence Centre who oversee all financial and banking transactions.

END

Reply:

(a) & (b) During this time government adopted an exploration strategy together with its implementation plan and augmented the funding for Council for Geoscience (CGS) to focus primarily on geo-mapping to support exploration. The CGS has now accelerated its mapping programme and launched a data portal to increase the efficacy of data access to all.

Reply:

Yes, the Department has commenced with the process of procuring a Mining Licensing System in collaboration with SITA with the intent to have the system operational within 1 year after procurement.

Reply:

1. PetroSA does not have a prepayment policy.

(a) See 1 above

(b) Not applicable, any change in policy has to be approved by the PetroSA Board

(2) (a) Payment for products is only released when the cargo vessel is docked at our seashores either in Mossel Bay or Cape Town and after confirmation received from PetroSA appointed Shipping Agents and Surveyors that the vessel has arrived and is ready to discharge and,

(b) The product is sampled upon vessel arrival, to confirmed that the cargo on board the vessel meets PetroSA Standard import specifications. PetroSA pays and takes title after all the samples and confirmation has been done. If it happened that the cargo is off spec, PetroSA would reject it without incurring any costs.

(3) There was no policy change as per 1 above, however, companies that transact with PetroSA are registered onto the National Treasury Database as well as PetroSA supplier database. There is a rigorous vetting process conducted by the PetroSA Treasury, Risk and Compliance Departments to ensure that suppliers listed on the database are in a position to deliver the requested products.

(4) If there is a contractual requirement for pre-payment, PetroSA rely on Regulation 31.1.2 (c) of the PFMA Treasury Regulations which authorises pre-payments only when contractual arrangements with suppliers bind the entity.

Reply:

Find here: Reply

Reply:

 

The road in question: D201, is a Provincial road that belongs to the North West Department of Public Works and Roads. This is an unpaved (gravel) road in the Greater Taung Local Municipality, which stretches from Pampierstad to Mokasa, approximately 24km long.

To improve the condition of this road (D201), the Province issued a tender on PWR 91/13 for “Upgrading from Gravel to Surface Standard”. The tender closed on 5 August 2021. The duration of the project is between January 2022 to July 2023 (18 months) but due to some delays, it is now expected to be completed by end of September 2023 which is less than two years. 

Reply:

Different provinces package psychosocial support to schools differently. However, in general, the support is given through a combination of direct appointments at schools, mainly at special schools, and support both from the provincial and district levels through the district-based support teams. It is therefore critical that the support given is viewed as such. The information provided is based on the data on PERSAL as of the end of February 2023. It includes both district/province-based and school-based posts.

(a)(i) counsellors, (aa) nationally (bb) in each province

PROVINCE	COUNSELLORS	TOTAL
	Office	School
GAUTENG	5		5
KWAZULU/NATAL	1		1
NORTHERN CAPE	1		1
WESTERN CAPE	2	39	41
Grand Total	9	39	48

 

 (ii) psychologists,(aa) nationally (bb) in each province

PROVINCE	PSYCHOLOGISTS	TOTAL
	Office	School
EASTERN CAPE	15	7	22
FREE STATE	8	6	14
GAUTENG	56	2	58
KWAZULU/NATAL	13		13
LIMPOPO PROVINCE	4		4
MPUMALANGA	9	4	13
NORTH WEST	2	1	3
NORTHERN CAPE	4		4
WESTERN CAPE	64	39	103
Grand Total	175	59	234

 

 (iii) psychiatrists 

The sector does not have the post of psychiatrists.

(iv) social workers who are employed in schools  

PROVINCE	SOCIAL WORKERS	TOTAL
	Office	School
EASTERN CAPE	53	1	54
FREE STATE	40	20	60
GAUTENG	137	20	157
KWAZULU/NATAL	68	5	73
LIMPOPO	62	9	71
MPUMALANGA	50		50
NORTH WEST	71		71
NORTHERN CAPE	20		20
WESTERN CAPE	95	1	96
Grand Total	596	56	652

 

 (b) vacancies in each case

 (i) nationally and  (ii) in each province?  

   

PROVINCE	COUNSELLORS	TOTAL
	Office	School
EAST CAPE	54		54
GAUTENG	3	1	4
LIMPOPO	5		5
NORTHERN CAPE	6	14	20
Grand Total	68	15	83

 

PROVINCE	PSYCHOLOGISTS	TOTAL
	Office	School
EAST CAPE	117	22	139
GAUTENG	13	5	18
KZN EDUCATION		4	4
LIMPOPO	2		2
MPUMALANGA	3		3
NORTH CAPE	8		8
NORTH WEST	29		29
WESTERN CAPE	20	20	40
Grand Total	192	51	243

                      

   

PROVINCE	SOCIAL WORKERS	TOTAL
	Office	School
EAST CAPE	65		65
FREE STATE	58		58
GAUTENG	5	1	6
KZN EDUCATION		10
LIMPOPO	4	7	11
NORTH CAPE	6		6
NORTH WEST E	8		8
WESTERN CAPE	13		13
Grand Total	159	18	177

           

Reply:

1. In accordance with the data as received from the Health Professions Council of South Africa (HPCSA), the following is the total number of

(a) General practitioners (i) nationally and (ii) in each province:

		PRACTICE_FIELD
REGISTER_NAME	PROVINCE	MEDICAL PRACTITIONER	MEDICAL PRACTITIONER - Restricted Practice	Grand Total
MEDICAL PRACTITIONER	Eastern Cape	2,513	24	2,537
	ex SWA	45		45
	Foreign	473	1	474
	Free State	1,186	18	1,204
	Gauteng	9,669	41	9,710
	Kwa Zulu Natal	5,582	21	5,603
	Limpopo	1,480	23	1,503
	Mpumalanga	1,457	25	1,482
	North West	1,076	23	1,099
	Northern Cape	610	36	646
	UNKNOWN	2		2
	Western Cape	5,939	5	5,944
	Province n/a	383	2	385
MEDICAL PRACTITIONER Total		30,415	219	30,634

 

(b) Specialist medical personnel (i) nationally and (ii) in each province:

Grand totals for all Specialities and all Sub-subspecialties

		PRACTICE_FIELD
REGISTER_NAME	PROVINCE	SPECIALIST	SUBSPECIALIST	Grand Total
MEDICAL PRACTITIONER	Eastern Cape	797	80	877
	ex SWA	37	1	38
	Foreign	344	27	371
	Free State	634	70	704
	Gauteng	5,534	853	6,387
	Kwa Zulu Natal	2,415	348	2,763
	Limpopo	259	14	273
	Mpumalanga	330	9	339
	North West	267	18	285
	Northern Cape	139	9	148
	UNKNOWN	2	1	3
	Western Cape	3,698	625	4,323
	Province n/a	162	25	187
MEDICAL PRACTITIONER Total		14,618	2,080	16,698

(c) Surgeons and (d) Paediatricians (i) nationally and (ii) in each province; -

		S P E C I A L I T Y
REGISTER_NAME	PROVINCE	NEURO- SURGERY	PAEDIATRICS	PAEDIATRIC SURGERY	SURGERY	Grand Total
MEDICAL PRACTITIONER	Eastern Cape	12	87	5	73	177
	ex SWA	1	3			4
	Foreign	2	27	1	15	45
	Free State	13	64	4	47	128
	Gauteng	107	575	27	404	1,113
	Kwa Zulu Natal	41	279	11	245	576
	Limpopo	5	44		15	64
	Mpumalanga	7	28		22	57
	North West	5	25		14	44
	Northern Cape	2	15		7	24
	UNKNOWN				1	1
	Western Cape	59	402	15	281	757
	Province n/a	3	15		13	31
MEDICAL PRACTITIONER Total		257	1,564	63	1,137	3,021

2. The current population for the Country is 60 604 087 as at March 2023. The table below provide the ratio breakdown per occupational category to the population.

Occupational Category Sum - count Total per 10 000 population General Practitioners 30634 5.054774606 Specialist medical personnel 16 698 2.755259723 Surgeons 1 394 0.230017490 Paediatricians 1 627 0.268463742

3. The table below provide a breakdown of (a) doctors, and (c) psychologists who registered with the Health Professions Council of South Africa (HPCSA) since 1 January 2013

NB (b) Nurses do not register with the HPCSA.

Doctors

			PRACTICE_FIELD
REGISTER_NAME	ORIGIN	CAT_FROM_ YEAR	General Practitioners	SPECIALIST	SUB SPECIALIST	Grand Total
MEDICAL PRACTITIONER	SOUTH AFRICAN	2013	1,249	486	77	1,812
		2014	1,244	497	100	1,841
		2015	1,344	670	94	2,108
		2016	1,333	700	72	2,105
		2017	1,105	541	99	1,745
		2018	1,418	519	87	2,024
		2019	1,528	583	73	2,184
		2020	1,583	423	95	2,101
		2021	1,874	625	83	2,582
		2022	2,339	654	83	3,076
		2023	1,947	179	26	2,152
	SOUTH AFRICAN Total		16,964	5,877	889	23,730
MEDICAL PRACTITIONER Total			16,964	5,877	889	23,730

	psychologists	CAT_FROM_YR
REGISTER_NAME	PRACTICE_FIELD	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	Grand Total
PSYCHOLOGIST	CLINICAL PSYCHOLOGY	113	101	150	156	114	108	116	134	73	102	50	1,217
	COMMUNITY SERVICE CLINICAL PSYCHOLOGY	87	155	146	118	108	124	119	74	99	99	50	1,179
	COUNSELLING PSYCHOLOGY	47	51	49	41	52	65	67	54	63	63	9	561
	EDUCATIONAL PSYCHOLOGY	51	70	47	62	62	74	54	48	73	67	22	630
	INDUSTRIAL PSYCHOLOGY	98	116	125	127	121	89	115	95	125	88	15	1,114
	NEUROPSYCHOLOGY								59	30	36	4	129
	RESEARCH PSYCHOLOGY	19	13	25	20	18	7	11	8	8	14	1	144
	(blank)	38	1										39
PSYCHOLOGIST Total		453	507	542	524	475	467	482	472	471	469	151	5,013

END.

Reply:

1. (a) See below the breakdown on the expenditure for the diesel consumption by the generators in each province:

Annexure A is attached and it covers a breakdown expenditure for diesel usage by generators for each hospital in the Republic.

b) Yes, the generators are in a workable condition.

2. I will not be making a statement on this matter.

END.

Reply:

National Skills Authority is not an entity of the Department of Employment and Labour. This entity resides in the other sister department. We can therefore reply to your question by stating what is in our purview, the total number of registered persons that have been registered in terms of the Electrical Installation Regulations of the Occupational Health and Safety Act, Act 85 of 1993, as amended, since 1 January 2015 is 8512. They are registered in the following categories:

Electrical Testers for Single Phase: 2814

Installation Electricians: 5387

Master Installation Electricians: 311

Reply:

Yes, I have been informed that Warmsand in the Northern Cape is a farmstead located approximately 20 kilometres from Keimoes and is therefore serviced from Keimoes when required. Patients from all surrounding areas including Eenduin, Friersdale and Warmsand are being served from Keimoes and not Upington as mentioned in the report. There is an Emergency Medical Services (EMS) station in Keimoes that services Warmsand area.

Due to shortage of staff, the service regressed because of the national measles campaign conducted throughout the province. The mobile clinic with the support from Keimoes Community Health Centre (CHC) staff will resume the services with effect from the 1st week of April 2023 in Warmsand and the surrounding areas.

END.

Reply:

1. The department is not aware of “historical concerns with regard to the influence of Mr Bill Gates over the South African healthcare system”. The Bill & Melinda Gates Foundation is one of many philanthropic organisations that contribute to healthcare across the globe. The Foundation “provides funding to organizations to achieve measurable impact in the fight against poverty, disease, and inequity around the world”, and “funds entrepreneurs, companies, and other organizations to create incentives that harness the power of private enterprise to create change for those who need it most.”

The Gates Foundation supports several programs in South Africa with its major focus on health. During the period 2009-2022, the Gates Foundation invested approximately $907 million dollars in South Africa to some 764 grantees and vendors (which include NGOs, universities, science councils, implementing partners, and manufacturers).

With specific reference to the vaccine programmes during COVID-19, departments and/or entities to which funds and/or donations were sent and/or directed by, include only one government entity, the SAMRC for the Sisonke healthcare worker COVID 19 vaccination programme, plus several private and non-government organisations.

With specific reference to SAHPRA since 1 January 2009 the Gates Foundation direct support to SAHPRA is $7.6million to date.

2. The Foundation has provided no direct funding to the NDoH since 1 January 2009 to date. The focus of the Foundation’s health investments is related to TB and HIV response and span the spectrum from discovery, translation science, product development and delivery of new interventions.

https://www.gatesfoundation.org/about/committed-grants?country=South%20Africa&region=AFRICA]

According to the Foundation the programmes and/or associations envisaged through the funding of the Foundation, include:

(i) in the current year:

• Technical Support to the TB Programme
• Technical Support on HIV quality improvement and HIV Prevention
• Technical support to the DDG NHI
• Catalytic support for scale up evidence-based TB and HIV interventions in South Africa
• SAHPRA was supported with paying for external reviewers (both South Africa and non-South African) selected by SAHPRA to address the large backlog (+/- 16000 applications) inherited from the MCC at the request of the SAHPRA Board. This included all products as the Gates Foundation support of external reviewers was not product specific
• Africa Resource Centre to provide technical assistance on Supply Chain management

(ii) envisaged for a later period:

• Provision of catalytic support to implement evidence-based TB and HIV interventions in South Africa

• Support to SAHPRA for digitisation of clinical trials records

END.

Reply:

I have no power to take steps to ensure that the Independent Electoral Commission obtains a seat on the Municipal Demarcation Board. The Board consists of no fewer than seven and no more than 10 members appointed by the President in accordance with section 8 of the Local Government: Municipal Demarcation Act No. 27 of 1998 (“the Act”). The Act also requires the selection panel to consider all applications and from amongst the applicants compile a list of nominees which must then be submitted to the Minister, whereafter the President must make the required number of appointments from the list.

End.

Reply:

1) The arrangement to get the medication from Cuba came into being when the country was faced with a crisis of COVID 19 and the whole country was in a state of disaster. The AGSA's findings indicated that the Department of Defence (DOD) did not follow procurement processes. The DOD then recorded the Rm33.4 as irregular expenditure due to AGSA's findings. The return of the medication back to Cuba came out of a court order which the department had to comply with.

2) There was no misrepresentation of facts, on the matter, the Department had always recorded the irregularity in the financial records as irregular expenditure.

3) (a) The irregular expenditure will be treated as per the irregular expenditure framework prescribed by National Treasury.
(b) The process indicated above will determine the outcome.

(c) There are no further relevant details surrounding the matter.

Reply:

1. I have directed the Director General of Health to meet with ESKOM to jointly seek interventions to mitigate against loadshedding. The first engagement took place on 22 September 2022. The meetings with Eskom are happening on a regular basis to seek for more exemptions of healthcare facilities. There are further ongoing engagements with both COGTA and various municipalities regarding additional exemptions for both private and public health care facilities from the grid.

2. No.

END.

Reply:

1. The Tembisa Hospital matter is still under investigation by the Special Investigating Unit (SIU). Once the investigation has been finalized, the Department will comply with any directives issued by the SIU. If such directives includes the blacklisting of the companies referred to, the Department will implement the recommendation.

2. (a) and (b) - No Department within the Public Health Sector have blacklisted any company since 01 January 2020 to date.

END.

Reply:

The honourable member should be aware that the Department of Employment and Labour is not the custodian of the production of official labour statistics in the country. The Quarterly Labour Force Survey (QLFS) and the Quarterly Employment Survey (QES) are quarterly produced by Statistics South Africa (StatsSA) and contain information on labour statistics.

However, the Department extracts and analyses labour statistics but the information is limited to what has been published. The total number of jobs that have been lost in the Republic by industry are provided and known but the survey questionnaires used by StatsSA does not cover the cause of jobs lost by industry.

In this context, there is probably no direct correlation between the ongoing energy crisis and the total number of jobs that have been lost using both survey data.

To the extent, researchers have reported a number of factors that could explain slow economic growth and low absorption rate in the country. These factors include electricity-load shedding, low investment, low savings, low international demand (low volume of exports) etc.

Reply:

1. The Interim Traditional Health Practitioners Council of South Africa (ITHPCSA/Council) has not been appointed. The appointment of the ITHPCSA was pending consultation between the Minister and the traditional health practitioners’ stakeholders. The consultation in this regard was held on 23-24 February 2023.

2. Regulation 6 of the Regulations relating to the appointment of members of the ITHPCSA provides that the Minister must publish the names of persons appointed to the Council in the Gazette. This regulation will be complied with upon finalization of the appointment of Members of the Council.

3. The Council once appointed will be expected to comply with the provisions of the Traditional Health Practitioners Act, 2007 (Act No. 22 of 2007).

4. The process to register traditional health practitioners will be undertaken subsequent to the appointment of the Council. Enquiries related to the registration and other matters can be directed to the Interim Registrar: Mr Kgereshi Mokwena as follows: (012) 3958018; (b) [email protected] (c) Dr AB Xuma Building, 1112 Voortrekker Rd, Pretoria Townlands 351-JR, Pretoria

END.

Reply:

1. Leave of absence in the Public Service is regulated in accordance with the Directive on Leave of Absence as published by the Department of Public Service and Administration in August 2021.

In accordance with the information as extracted from the PERSAL data set-

a) (i) The data as provided gives overall number of days counts that Nurses (in all categories as employed in the Public Health Sector) took in different leave categories during the financial years 2021/2022 and 2002/2023 is as per the table below:

The tables below provide a breakdown of the various categories of absenteeism per provinces.

NUMBER OF DAYS ABSENT BY NURSES (IN ALL CATEGORIES)
	EC	FS	GAU	KZN	LP	MPU	NW	NC	WC	Overall Total
Adoption (Workdays)	2	44	0	4	6	0	0	0	0	56
Discounting (Workdays)	102	1964	102	791	238	148	136	33	852	4366
Family Responsibility (Workdays)	7403	1542	2147	20103	14428	3755	2776	384	11203	63741
Gratuity (Workdays)	239	131	34	713	531	199	82	26	265	2220
Leave Without Pay (Calendar Days)	1540	269	359	3409	595	291	183	130	1421	8197
Maternity	576	163	217	1290	742	362	184	22	524	4080
Occupational Injuries/Diseases (Workdays)	185	41	67	833	1735	988	151	9	158	4167
Paternity (Workdays)	54	12	16	105	100	27	24	1	48	387
Permanent Incapacity Leave	7	1	121	13	598	3	155	9	7	914
Pre-Natal (Workdays)	308	161	154	1376	350	194	77	13	861	3494
Shop Steward/Office Bearer (Workdays)	663	183	87	1024	1052	258	183	78	595	4123
Sick-Full Pay (Workdays)	53276	19217	11953	145227	57858	17671	14473	2504	59599	381778
Special (Workdays)	1893	536	459	10173	3249	601	778	104	10795	28588
Temporary Incapacity Leave	1011	773	583	3358	872	431	343	37	1507	8915
Vacation - Full Pay (Workdays)	103013	37979	17654	214258	91977	38302	25891	4459	75251	608784

(ii) The Public Health Services does not make provision for a Job title of Operational Staff. It is requested that clear indication be provided on what is the meaning of Operational Staff.

(iii) The data as provided gives overall number of days counted that Clinicians (Medical Officers/ Specialist and Registrar’s) took in different leave categories during the financial years 2021/2022 and 2002/2023 is as per the table below.

The tables below provide a breakdown of the various categories of absenteeism per provinces.

NUMBER OF DAYS ABSENT BY CLINITIANS MEDICAL OFFICER / SPECIALIST / REGISTRARS
	EC	FS	GAU	KZN	LP	MPU	NW	NC	WC	Overall Total
Adoption (Workdays)	1	0	0	0	0	2	0	0	1	4
Discounting (Workdays)	14	49	35	206	157	36	69	5	317	888
Family Responsibility (Workdays)	265	174	146	1491	906	284	146	37	726	4175
Gratuity (Workdays)	17	1	0	19	19	10	2	0	16	84
Leave Without Pay (Calendar Days)	20	19	38	261	262	29	18	0	163	810
Maternity	58	40	51	239	161	78	46	3	158	834
Occupational Injuries/Diseases (Workdays)	13	2	16	99	173	107	12	0	11	433
Paternity (Workdays)	20	17	14	99	77	20	15	5	74	341
Permanent Incapacity Leave	0	0	0	0	0	0	0	0	1	1
Pre-Natal (Workdays)	51	15	27	407	118	28	15	1	112	774
Shop Steward/Office Bearer (Workdays)	3	0	2	17	37	15	0	0	118	192
Sick-Full Pay (Workdays)	2011	962	1293	17565	4604	1862	928	184	6852	36261
Special (Workdays)	572	801	263	3440	1328	409	226	33	4505	11577
Temporary Incapacity Leave	19	33	16	140	18	9	10	2	95	342
Vacation - Full Pay (Workdays)	7990	5993	4328	34780	13685	6903	4198	651	23370	101898

2. The National Department of Health is consulting with the Provincial Departments of Health to collate the full details in this regard.

END.

Reply:

(a)-(b) All health facilities have been affected by the load-shedding across the country and some core services, especially surgical interventions often have to be rescheduled. Fortunately, all hospitals have two back-up suppliers (e.g. generators and Uninterrupted Power Suppliers for theatres and ICU’s) and most of the Community Health Centres have one back-up supplier (e.g. generators). These back-up suppliers have assisted in reducing the impact of load-shedding and preventing untold harm to the patients. All health facilities are continuously adapting to ensure that they function optimally.

END.

Reply:

(1) My Department has appointed CSIR to conduct a due diligence exercise regarding the roll-out of solar energy to all health facilities across the country. (a) The proposed solar energy programme is going to cover the roll-out of the solar energy + battery storage as back-up supply to all the clinics, CHC’s, hospitals, EMS centres including the forensic laboratories. The objective of the exercise by CSIR is to identify the required critical consumption for critical areas of each health facility so that the department can be able:

- To compile a comprehensive business case that will assist the Department in justifying for the required budget;

- To identify critical areas within a “health facility” that requires a back-up service from the solar energy. CSIR is going to quantify the required size of solar energy for those critical areas;

- CSIR is going to consider different kits of inverters with batteries for the Clinics and CHC’s. Unlike solar panels, these kits are not easy to steal. They can be stored in a lockable room with burglar bars and with strict access control;

- To map out the roll-out implementation program for the required solar energy solution for each health facility;

- The study will also identify areas that can be funded by other donors like USAID including others that are interested to partner with the National Department of Health; and

- The exercise/study is expected to be completed at the end of April 2023.

(b) The expected start date of the roll-out of the solar energy programme is June 2023 depending on the availability of funding from the National State of Disaster Centre.

(c) The envisage completion date is going to be informed by the detailed analysis by CSIR.

(2) No.

END.

Reply:

In terms of the Constitution (Section 139 and its subsections) the prerogative to intervene in municipalities is bestowed upon the Provincial Government, having assessed the municipal deficiencies in fulfilling its Executive Obligations. Such an assessment ought to establish ‘clearly’, amongst others, political interference as a factor.

To the extent that two interventions were invoked in Emfuleni local municipality, with another recently terminated, a close-out report is being prepared by the Gauteng Provincial Executive Committee, which should indicate the nature and extent of the challenges that remain, and the proposed plan to address those, and whether political interference is among the remaining challenges.

The Emfuleni intervention close-out report should likewise indicate progress made on instituting disciplinary processes, where evidence exist, on officials identified to have transgressed the prescripts governing municipalities, including the implementation of the investigation reports indicated during the Portfolio Committee visit.

End.

Reply:

a) The total number of-

(i) As per the HPCSA register, a total of 16 964 doctors have been trained in the Republic since 01 January 2013.

(ii) As per the SA Nursing Council register, a total of 181 277 Nurses (all categories) have been trained in the Republic since 1 January 2013.

(iii) A total of 5 877 specialists have registered with the Health Professions Council of South Africa (HPCSA) after training in different fields of Specialty in the Republic since 1 January 2013.

b) Of the above trained numbers, the following have been absorbed in the Public Health Sector

(i) Doctors appointed since January 2013 in Public Health Sector is 15 606,

(ii) Nurses (all categories) appointed since January 2013 in Public Health Sector is 52 542 and

(iii) Medical Specialist appointed since January 2013 in the Public Health Sector is 4 293.

 

END.

Reply:

Find here: REPLY

Reply:

(1) The list of contacted suppliers is available on the National Department of Health’s website, at the following url: https://www.health.gov.za/tenders/

Click on the tab: Master Health Product List.

1. See attached document with list of essential medicines where contracts were awarded to one supplier only on pages 1–21;
2. See attached document with list of essential medicines where contracts were awarded to more than supplier only from page 22 onwards.

(2) The decision to award a contract to one supplier only is informed by a number of factors including the following:

• The product is only available from one supplier registered with SAHPRA (i.e. sole supplier);
• During the contracting process, a bid was only received from one registered supplier even if there are other suppliers in the market;
• The estimated tender volumes are too low to justify award to more than one supplier as this decreases the benefits derived from economies of scale.

(3) It is the standard practice of the Department of Health to award more than one supplier in to manage risks related to supply challenges for certain strategic products that are important for successful implementation of public health programmes.

The decision to award contracts to more than one supplier depends on factors such as the following:

• The estimated tender volumes are high because of high disease burden, as in the case of first line antiretrovirals used in the management of HIV;
• The highest scoring bidder does not have the capacity to meet estimated tender volumes and their inability to meet demand during a contract period would result in a supply challenge;
• There is a risk to public health if the medicine is not available.

END.

Annexure 1

Medicine Description (More than one contracted supplier)

• Abacavir; 20mg/ml; Solution; 240 ml
• Allopurinol; 300mg; Tablet; 30 Tablets
• Amitriptyline; 25mg; Tablet; 28 Tablets
• Amlodipine; 10mg; Tablet; 28 Tablets
• Amlodipine; 5mg; Tablet; 28 Tablets
• Amoxicillin, Clavulanic Acid; 125mg/5ml, 31.25mg/5ml; Suspension; 100 ml
• Amoxicillin, Clavulanic Acid; 250mg, 125mg; Tablet; 15 Tablets
• Amoxicillin, Clavulanic Acid; 250mg/5ml, 62.5mg/5ml; Suspension; 100 ml
• Amoxicillin, Clavulanic Acid; 875mg, 125mg; Tablet; 10 Tablets
• Amoxicillin; 125mg/5ml; Suspension; 100 ml
• Amoxicillin; 250mg/5ml; Suspension; 100 ml
• Amoxicillin; 250mg; Capsule; 15 Capsules
• Amoxicillin; 500mg; Capsule; 15 Capsules
• Ampicillin; 250mg; injection; 1 Injection
• Ampicillin; 500mg; injection; 1 Injection
• Aspirin; 300mg; tablet, scored; 14 Tablets
• Atenolol; 50mg; Tablet; 30 Tablets
• Atorvastatin; 10mg; Tablet; 28 Tablets
• Atropine; 1mg/ml; injection; 1 ml
• Atropine; 500mcg/ml; injection; 1 ml
• Azithromycin; 500mg; Tablet; 2 Tablets
• Azithromycin; 500mg; Tablet; 3 Tablets
• Calcium Carbonate, Glycine; 420mg, 180mg; Tablet; 168 Tablets
• Calcium Carbonate; 500mg; Tablet; 10 Tablets
• Calcium Carbonate; 500mg; Tablet; 30 Tablets
• Carbamazepine; 200mg; Tablet; 56 Tablets
• Carbamazepine; 200mg; Tablet; 84 Tablets
• Cefazolin; 1g; injection; 1 Injection
• Cefazolin; 500mg; injection; 1 Injection
• Ceftriaxone; 1g; injection; 1 Injection
• Ceftriaxone; 250mg; injection; 1 Injection
• Ceftriaxone; 500mg; injection; 1 Injection
• Cetirizine; 10mg; Tablet; 28 Tablets
• Chlorphenamine; 2mg/5ml; Syrup; 50 ml
• Ciprofloxacin; 500mg; Tablet; 10 Tablets
• Citalopram; 20mg; Tablet; 28 Tablets
• Clotrimazole; 1%; Cream; 20 g
• Clotrimazole; 500mg/50g; cream, vaginal; 50 g
• Dexamethasone; 4mg/ml; injection; 1 ml
• Diclofenac; 75mg/3ml; Injection; 3 ml
• Dolutegravir; 50mg; Tablet; 30 Tablets
• Doxazosin; 4mg; Tablet; 30 Tablets
• Doxycycline; 100mg; Tablet; 14 Tablets
• Efavirenz; 200mg; Tablet; 84 Tablets
• Efavirenz; 600mg; Tablet; 28 Tablets
• Enalapril; 10mg; Tablet; 28 Tablets
• Enalapril; 20mg; Tablet; 30 Tablets
• Enalapril; 5mg; Tablet; 28 Tablets
• Epinephrine (Adrenaline); 1mg/ml; injection; 1 ml
• Fentanyl; 100mcg/2ml; injection; 2 ml
• Ferrous Sulfate Co; 170mg; Tablet; 28 Tablets
• Flucloxacillin; 250mg; Capsule; 20 Capsules
• Flucloxacillin; 250mg; Capsule; 40 Capsules
• Fluoxetine; 20mg; Capsule; 28 Capsules
• Folic Acid; 5mg; Tablet; 28 Tablets
• Furosemide; 40mg; Tablet; 28 Tablets
• Furosemide; 40mg; Tablet; 56 Tablets
• Furosemide; 40mg; Tablet; 84 Tablets
• Glibenclamide; 5mg; Tablet; 28 Tablets
• Glibenclamide; 5mg; Tablet; 56 Tablets
• Glimepiride; 1mg; Tablet; 28 Tablets
• Glimepiride; 2mg; Tablet; 28 Tablets
• Glimepiride; 4mg; Tablet; 28 Tablets
• Hydrochlorothiazide; 25mg; Tablet; 28 Tablets
• Hydrocortisone; 100mg/2ml; injection; 2 ml
• Ibuprofen; 200mg; Tablet; 15 Tablets
• Ibuprofen; 200mg; Tablet; 42 Tablets
• Ibuprofen; 200mg; Tablet; 84 Tablets
• Ibuprofen; 400mg; Tablet; 15 Tablets
• Isoniazid; 100mg; Tablet; 28 Tablets
• Isoniazid; 300mg; Tablet; 28 Tablets
• Lamivudine, Abacavir, Dolutegravir; 300mg, 600mg, 50mg; Tablet; 28 Tablets
• Lamivudine, Abacavir; 300mg, 600mg; Tablet; 28 Tablets
• Lamivudine, Abacavir; 60mg, 120mg; Tablet; 28 Tablets
• Lamivudine; 10mg/ml; Solution; 240 ml
• Lamivudine; 150mg; Tablet; 56 Tablets
• Lansoprazole; 30mg; Capsule; 28 Capsules
• Loperamide; 2mg; Tablet; 6 Tablets
• Lopinavir, Ritonavir; 200mg, 50mg; Tablet; 112 Tablets
• Metformin; 500mg; Tablet; 56 Tablets
• Metformin; 500mg; Tablet; 84 Tablets
• Metformin; 850mg; Tablet; 28 Tablets
• Metformin; 850mg; Tablet; 56 Tablets
• Metformin; 850mg; Tablet; 84 Tablets
• Metoclopramide; 10mg; Tablet; 10 Tablets
• Metronidazole; 400mg; Tablet; 14 Tablets
• Metronidazole; 400mg; Tablet; 5 Tablets
• Metronidazole; 500mg/100ml; injection; 100 ml
• Midazolam; 15mg/3ml; injection; 3 ml
• Midazolam; 5mg/5ml; injection; 5 ml
• Morphine; 10mg/ml; injection; 1 ml
• Morphine; 15mg/ml; injection; 1 ml
• Omeprazole; 20mg; Capsule; 14 Capsules
• Oxytocin; 10IU/ml; injection; 1 ml
• Pantoprazole; 20mg; Tablet; 30 Tablets
• Paracetamol; 500mg; Tablet; 100 Tablets
• Paracetamol; 500mg; Tablet; 20 Tablets
• Pethidine; 100mg/2ml; injection; 2 ml
• Pethidine; 50mg/ml; injection; 1 ml
• Prednisone; 5mg; Tablet; 28 Tablets
• Rifampicin, Isoniazid; 150mg, 75mg; Tablet; 56 Tablets
• Rifampicin, Isoniazid; 150mg, 75mg; Tablet; 84 Tablets
• Rifampicin, Isoniazid; 300mg, 150mg; Tablet; 56 Tablets
• Rifampicin, Pyrazinamide, Ethambutol, Isoniazid; 150mg, 400mg, 275mg, 75mg; Tablet; 112 Tablets
• Rifampicin, Pyrazinamide, Ethambutol, Isoniazid; 150mg, 400mg, 275mg, 75mg; Tablet; 56 Tablets
• Rifampicin, Pyrazinamide, Ethambutol, Isoniazid; 150mg, 400mg, 275mg, 75mg; Tablet; 84 Tablets
• Salbutamol; 100mcg; Inhaler; 200 Doses
• Simvastatin; 10mg; Tablet; 28 Tablets
• Simvastatin; 20mg; Tablet; 28 Tablets
• Sodium Chloride; 0.9%; injection; 10 ml
• Spironolactone; 25mg; Tablet; 28 Tablets
• Sulfamethoxazole, Trimethoprim; 200mg/5ml, 40mg/5ml; Suspension; 100 ml
• Sulfamethoxazole, Trimethoprim; 400mg, 80mg; Tablet (Co-trimoxazole); 28 Tablets
• Sulfamethoxazole, Trimethoprim; 400mg, 80mg; Tablet (Co-trimoxazole); 56 Tablets
• Tenofovir, Emtricitabine, Efavirenz; 300mg, 200mg, 600mg; Tablet; 28 Tablets
• Tenofovir, Emtricitabine, Efavirenz; 300mg, 200mg, 600mg; Tablet; 84 Tablets
• Tenofovir, Emtricitabine; 300mg, 200mg; Tablet; 28 Tablets
• Tenofovir, Lamivudine, Dolutegravir; 300mg, 300mg, 50mg; Tablet; 84 Tablets
• Tenofovir, Lamivudine, Dolutegravir; 300mg, 300mg, 50mg; Tablet; 28 Tablets
• Tramadol; 50mg; Capsule; 100 Capsules
• Tramadol; 50mg; Capsule; 20 Capsules
• Vitamin B1 (Thiamine); 100mg; Tablet; 28 Tablets
• Vitamin B6 (Pyridoxine); 25mg; Tablet; 28 Tablets

Annexure 2

Medicine Description (One contracted supplier)

• Abacavir; 300mg; Tablet; 56 Tablets
• Abacavir; 60mg; Tablet, dispersible; 56 Tablets
• Acetazolamide; 250mg; Tablet; 100 Tablets
• Acetazolamide; 250mg; Tablet; 30 Tablets
• Acetic Acid; Liquid; 500 ml
• Acetylcysteine; 200mg/ml; injection; 10 ml
• Acetylcysteine; 200mg; Tablet; 20 Tablets
• Aciclovir; 200mg; Tablet, dispersible; 25 Tablets
• Aciclovir; 250mg; injection; 1 Injection
• Aciclovir; 400mg; Tablet, dispersible; 70 Tablets
• Adenosine; 6mg/2ml; injection; 2 ml
• Albendazole; 400mg; Tablet; 1 Tablet
• Albumin, Human, Normal; 20%; Infusion (parenteral); 100 ml
• Albumin, Human, Normal; 20%; Infusion (parenteral); 50 ml
• Alfentanil; 1mg/2ml; injection; 2 ml
• Allopurinol; 100mg; Tablet; 100 Tablets
• Allopurinol; 100mg; Tablet; 28 Tablets
• Allopurinol; 100mg; Tablet; 56 Tablets
• Alprazolam; 0.5mg; Tablet; 30 Tablets
• Alprostadil; 500mcg/ml; injection; 1 ml
• Alteplase; 50mg; injection; 1 Injection
• Aluminium hydroxide; 300mg/5ml; Suspension; 500 ml
• Amikacin Sulph; 100mg/2ml; injection; 2 ml
• Amikacin Sulph; 250mg/2ml; injection; 2 ml
• Amikacin Sulph; 500mg/2ml; injection; 2 ml
• Aminophylline; 250mg/10ml; injection; 10 ml
• Amiodarone; 150mg/3ml; injection; 3 ml
• Amiodarone; 200mg; Tablet; 30 Tablets
• Amisulpride; 200mg; Tablet; 30 Tablets
• Amisulpride; 50mg; Tablet; 30 Tablets
• Amitriptyline; 10mg; Tablet; 100 Tablets
• Amitriptyline; 10mg; Tablet; 28 Tablets
• Amitriptyline; 25mg; Tablet; 100 Tablets
• Amitriptyline; 25mg; Tablet; 168 Tablets
• Amitriptyline; 25mg; Tablet; 500 Tablets
• Amitriptyline; 25mg; Tablet; 56 Tablets
• Amitriptyline; 25mg; Tablet; 84 Tablets
• Amoxicillin, Clavulanic Acid; 1,000mg, 200mg; injection; 1 Injection
• Amoxicillin, Clavulanic Acid; 500mg, 100mg; injection; 1 Injection
• Amoxicillin/Clavulanic Acid; 600mg/42.9mg; Suspension; 100 ml
• Amoxicillin; 250mg; Capsule; 100 Capsules
• Amoxicillin; 500mg; Capsule; 100 Capsules
• Anastrozole; 1mg; Tablet; 28 Tablets
• Aqueous; Cream; 100 g
• Aqueous; Cream; 500 g
• Aripiprazole; 10mg; Tablet; 30 Tablets
• Aripiprazole; 15mg; Tablet; 30 Tablets
• Aripiprazole; 5mg; Tablet; 30 Tablets
• Artemether, Lumefantrine; 20mg, 120mg; Tablet; 24 Tablets
• Artesunate; 60mg; injection; 1 Injection
• Aspirin; 300mg; Tablet; 96 Tablets
• Atazanavir, Ritonavir; 300mg, 100mg; Tablet; 28 Tablets
• Atazanavir; 200mg; Capsule; 60 Capsules
• Atazanavir; 300mg; Capsule; 30 Capsules
• Atenolol; 100mg; Tablet; 28 Tablets
• Atenolol; 25mg; Tablet; 28 Tablets
• Atorvastatin; 20mg; Tablet; 30 Tablets
• Atorvastatin; 40mg; Tablet; 30 Tablets
• Atracurium; 25mg/2.5ml; injection; 2.5 ml
• Atracurium; 50mg/5ml; injection; 5 ml
• Atropine; 1%; Drop, Eye; 5 ml
• Azathioprine; 50mg; Tablet; 100 Tablets
• Balanced Salt; solution, ophthalmic; 15 ml
• Balanced Salt; solution, ophthalmic; 500 ml
• Barium Sulfate With Suspending Agent; 4.6%; Suspension; 225 ml
• Barium Sulfate With Suspending Agent; 98g/100g; Powder; 340 g
• Barium Sulfate; BP; Suspension; 1 Kit
• Beclometasone; 100mcg; Inhaler; 200 Doses
• Beclometasone; 100mcg; Inhaler; SERIES; 200 Doses
• Beclometasone; 200mcg; Inhaler; 200 Doses
• Beclometasone; 50mcg; Inhaler; 200 Doses
• Beclometasone; 50mcg; Inhaler; SERIES; 200 Doses
• Beclometasone; 50mcg; Spray, Nasal; 150 Doses
• Benzoin Co; Tincture; 100 ml
• Benzoin Co; Tincture; 20 ml
• Benzydamine, Chlorhexidine; 22.5mg/15ml, 18mg/15ml; Mouthwash; 200 ml
• Benzyl Benzoate; 25%; Liquid; 100 ml
• Betamethasone Disodium Phosphate; 4mg/ml; injection; 1 ml
• Betamethasone Valerate; 0.1%; Cream; 15 g
• Betamethasone Valerate; 0.1%; Cream; 50 g
• Betamethasone Valerate; 0.1%; Cream; 500 g
• Betamethasone; 500mcg; Tablet; 100 Tablets
• Betamethasone; 500mcg; Tablet; 20 Tablets
• Betaxolol; 2.5mg/ml; Drop, Eye; 5 ml
• Betaxolol; 5mg/ml; Drop, Eye; 5 ml
• Bevacizumab; 100mg/4ml; injection; 4 ml
• Bezafibrate; 400mg; Tablet; 30 Tablets
• Bimatoprost; 0.3mg/ml; Drop, Eye; 3 ml
• Biperiden; 2mg; Tablet; 100 Tablets
• Biperiden; 5mg/ml; injection; 1 ml
• Bisacodyl; 10mg; Suppository; 10 Suppositories
• Bleomycin; 15IU; injection; 1 Injection
• Bortezomib; 3.5mg; injection; 10 ml
• Botulinum Toxin, Type A, Lyophilised; 100IU; injection; 1 Injection
• Brimonidine; 1.5mg/ml; Drop, Eye; 5 ml
• Brimonidine; 2mg/ml; Drop, Eye; 5 ml
• Bromocriptine; 2.5mg; Tablet; 30 Tablets
• Budesonide, Formoterol; 160mcg, 4.5mcg; Inhaler; 60 Doses
• Budesonide, Formoterol; 320mcg, 9mcg; Inhaler; 60 Doses
• Bupivacaine, Adrenaline; 5mg/ml, 5mcg/ml; injection; 20 ml
• Bupivacaine, Dextrose; 5mg, 72.7mg; injection; 4 ml
• Bupivacaine; 5mg/ml; injection (Spinal); 10 ml
• Bupivacaine; 5mg/ml; injection (Spinal); 4 ml
• Busulfan; 2mg; Tablet; 100 Tablets
• Caffeine; 20mg/ml; injection; 1 ml
• Calamine; Lotion; 100 ml
• Calcium Folinate; 100mg; injection; 1 Injection
• Calcium Folinate; 15mg; Tablet; 10 Tablets
• Calcium Folinate; 300mg; injection; 1 Injection
• Calcium Gluconate; 10%; injection; 10 ml
• Capecitabine; 150mg; Tablet; 60 Tablets
• Capecitabine; 500mg; Tablet; 120 Tablets
• Captopril; 25mg; Tablet; 60 Tablets
• Carbamazepine; 100mg/5ml; Suspension; 250 ml
• Carbamazepine; 200mg; Tablet; 100 Tablets
• Carbamazepine; 200mg; Tablet; 28 Tablets
• Carbimazole; 5mg; Tablet; 100 Tablets
• Carboplatin; 150mg/15ml; injection; 15 ml
• Carboplatin; 450mg/45ml; injection; 45 ml
• Carvedilol; 12.5mg; Tablet; 28 Tablets
• Carvedilol; 25mg; Tablet; 30 Tablets
• Cefalexin; 125mg/5ml; Suspension; 100 ml
• Cefalexin; 250mg/5ml; Suspension; 100 ml
• Cefalexin; 250mg; Capsule; 20 Capsules
• Cefalexin; 500mg; Capsule; 20 Capsules
• Cefepime; 1g; injection; 1 Injection
• Cefepime; 2g; injection; 1 Injection
• Cefotaxime; 1g; injection; 1 Injection
• Cefotaxime; 500mg; injection; 1 Injection
• Ceftazidime; 1g; injection; 1 Injection
• Ceftazidime; 2g; injection; 1 Injection
• Cetirizine; 1mg/ml; Syrup; 150 ml
• Chlorambucil; 2mg; Tablet; 25 Tablets
• Chloramphenicol; 0.5%; Drop, Eye; 10 ml
• Chloramphenicol; 1%; ointment, eye; 3.5 g
• Chlorhexidine, Alcohol; 0.5%, 70%; Solution (without emolient); 500 ml
• Chlorhexidine, Alcohol; 0.5%, 70%; Solution; 50 ml
• Chlorhexidine; 0.2%; Mouthwash; 200 ml
• Chlorhexidine; 4%; Solution (Hibiscrub); 500 ml
• Chlorphenamine; 4mg; Tablet; 10 Tablets
• Chlorphenamine; 4mg; Tablet; 30 Tablets
• Chlorpromazine; 100mg; Tablet; 56 Tablets
• Chlorpromazine; 25mg; Tablet; 56 Tablets
• Ciclosporin; 100mg/ml; Solution; 50 ml
• Ciclosporin; 100mg; Capsule; 50 Capsules
• Ciclosporin; 25mg; Capsule; 50 Capsules
• Ciclosporin; 50mg; injection; 1 Injection
• Ciprofloxacin; 100mg/50ml; injection; 100 ml
• Ciprofloxacin; 250mg/5ml; Suspension; 100 ml
• Ciprofloxacin; 250mg; Tablet; 10 Tablets
• Ciprofloxacin; 3mg/ml; Drop, Eye; 5 ml
• Ciprofloxacin; 400mg/200ml; Infusion (parenteral); 200 ml
• Cisatracurium; 10mg/5ml; injection; 5 ml
• Cisatracurium; 5mg/2.5ml; injection; 2.5 ml
• Cisplatin; 10mg/10ml; injection; 10 ml
• Cisplatin; 50mg/50ml; injection; 50 ml
• Citalopram; 10mg; Tablet; 30 Tablets
• Clarithromycin; 125mg/5ml; Suspension; 60 ml
• Clarithromycin; 250mg/5ml; Suspension; 60 ml
• Clarithromycin; 500mg; Tablet; 14 Tablets
• Clindamycin; 150mg; Capsule; 100 Capsules
• Clindamycin; 150mg; Capsule; 20 Capsules
• Clindamycin; 600mg/4ml; injection; 4 ml
• Clobetasol; 0.05%; Cream; 25 g
• Clobetasol; 0.05%; Ointment; 25 g
• Clomifene; 50mg; Tablet; 10 Tablets
• Clomipramine; 25mg; Tablet; 50 Tablets
• Clonazepam; 0.5mg; Tablet; 84 Tablets
• Clonazepam; 2mg; Tablet; 84 Tablets
• Clopidogrel; 75mg; Tablet; 30 Tablets
• Clotiapine; 40mg/4ml; injection; 4 ml
• Clotrimazole; 500mg; Pessary; 1 Pessary
• Cloxacillin; 250mg; injection; 1 Injection
• Cloxacillin; 500mg; injection; 1 Injection
• Clozapine; 100mg; Tablet; 100 Tablets
• Clozapine; 25mg; Tablet; 100 Tablets
• Coal Tar; BP; Solution; 500 ml
• Codeine Phosphate; 30mg; Tablet; 100 Tablets
• Colchicine; 500mcg; Tablet; 12 Tablets
• Cyclopentolate, Phenylephrine; 0.2%, 1%; Drop, Eye; 5 ml
• Cyclopentolate; 1%; Drop, Eye; 15 ml
• Cyclophosphamide; 1g; injection; 1 Injection
• Cyclophosphamide; 500mg; injection; 1 Injection
• Cyclophosphamide; 50mg; Tablet; 50 Tablets
• Cyproterone, Ethinylestradiol; 2mg, 0.035mg; Tablet; 28 Tablets
• Cyproterone; 10mg; Tablet; 15 Tablets
• Cyproterone; 50mg; Tablet; 20 Tablets
• Dacarbazine; 200mg; injection; 1 Injection
• Dapsone; 100mg; Tablet; 100 Tablets
• Darunavir, Ritonavir; 400mg, 50mg; Tablet; 56 Tablets
• Deferasirox; 250mg; Tablet; 28 Tablets
• Deferasirox; 500mg; Tablet; 28 Tablets
• Deferoxamine; 500mg; injection; 1 Injection
• Desmopressin; 0.1mg; Tablet; 30 Tablets
• Desmopressin; 0.2mg; Tablet; 30 Tablets
• Desmopressin; 100mcg/ml; Spray, Nasal; 5 ml
• Desmopressin; 4mcg/ml; injection; 1 Injection
• Dexamethasone; 0.1%; Drop, Eye; 5 ml
• Dextrose In Water; 50%; injection; 20 ml
• Dextrose In Water; 50%; injection; 50 ml
• Dextrose Monohydrate; BP; Powder; 500 g
• Dextrose Monohydrate; BP; Powder; 75 g
• Dextrose, Electrolyte; 5%; Infusion (parenteral); 1 L
• Dextrose, Maintelyte; 10%; Infusion (parenteral); 1 L
• Dextrose, Maintelyte; 5%; Infusion (parenteral); 1 L
• Dextrose; 10%; Infusion (parenteral); 1 L
• Dextrose; 5%; Infusion (parenteral); 1 L
• Dextrose; 5%; Infusion (parenteral); 100 ml
• Dextrose; 5%; Infusion (parenteral); 200 ml
• Dextrose; 5%; Infusion (parenteral); 50 ml
• Dextrose; 50%; Infusion (parenteral); 500 ml
• Diazepam; 10mg/2ml; injection; 2 ml
• Diazepam; 5mg; Tablet; 100 Tablets
• Diazepam; 5mg; Tablet; 14 Tablets
• Diazoxide; 20mg; Capsule; 100 Capsules
• Digoxin; 250mcg; Tablet; 30 Tablets
• Digoxin; 62.5mcg; Tablet; 100 Tablets
• Dinoprostone; 0.5mg; Tablet; 10 Tablets
• Dinoprostone; 1mg/3g; Syringe, Prefilled; 3 g
• Dobutamine; 250mg/20ml; injection; 20 ml
• Docetaxel; 20mg/ml; injection; 1 ml
• Docetaxel; 80mg/4ml; injection; 4 ml
• Dolutegravir; 50mg; tablet, scored; 30 Tablets
• Dopamine; 200mg/5ml; injection; 5 ml
• Doxorubicin; 10mg/5ml; injection; 5 ml
• Doxorubicin; 50mg/25ml; injection; 25 ml
• Doxycycline; 100mg; Tablet; 100 Tablets
• Efavirenz; 50mg; Capsule; 28 Capsules
• Electrolyte No 2 Solution: Na, K, Cl, Mg, Hpo4, Dextrose; injection; 1 L
• Emulsifying; BP; Ointment; 500 g
• Enoxaparin; 40mg/0.4ml; Syringe, Prefilled; 0.4 ml
• Enoxaparin; 60mg/0.6ml; Syringe, Prefilled; 0.6 ml
• Enoxaparin; 80mg/0.8ml; Syringe, Prefilled; 0.8 ml
• Epinephrine (Adrenaline); 0.15mg/0.3ml; auto-pen; 0.3 ml
• Epinephrine (Adrenaline); 0.3mg/0.3ml; auto-pen; 0.3 ml
• Epirubicin; 10mg/5ml; injection; 5 ml
• Epirubicin; 50mg/25ml; injection; 25 ml
• Ergometrine, Oxytocin; 500mcg, 5IU; injection; 1 ml
• Ertapenem; 1g; injection; 1 Injection
• Erythropoietin; 10000IU; injection; 1 ml
• Erythropoietin; 2000IU/0.3ml; Syringe, Prefilled; 1 Syringe, Pre-filled
• Erythropoietin; 30000IU/0.6ml; Syringe, Prefilled; 1 Syringe, Pre-filled
• Erythropoietin; 4000IU; injection; 1 ml
• Erythropoietin; 6000IU; injection; 1 ml
• Estradiol, Norethisterone Acetate; 1mg, 0.5mg; Tablet; 28 Tablets
• Estradiol, Norethisterone Acetate; 2mg, 1mg; Tablet; 28 Tablets
• Estradiol; 1mg; Tablet; 28 Tablets
• Estradiol; 2mg; Tablet; 28 Tablets
• Estrogen, Conjugated ; 0.3mg; Tablet; 28 Tablets
• Ethambutol; 400mg; Tablet; 100 Tablets
• Ethambutol; 400mg; Tablet; 56 Tablets
• Ethambutol; 400mg; Tablet; 84 Tablets
• Ethionamide; 250mg; Tablet; 250 Tablets
• Ethionamide; 250mg; Tablet; 28 Tablets
• Ethionamide; 250mg; Tablet; 56 Tablets
• Ethionamide; 250mg; Tablet; 84 Tablets
• Etomidate; 20mg/10ml; injection; 10 ml
• Etonogestrel; 68mg; Implant; 1 Device
• Etoposide; 100mg; injection (Section 21); 1 Injection
• Exemestane; 25mg; Tablet; 28 Tablets
• Fenoterol; 1.25mg/2ml; solution, inhalation; 60 UDVs (2ml)
• Fentanyl; 500mcg/10ml; injection; 10 ml
• Ferrous Gluconate; 350mg/5ml; Syrup; 100 ml
• Ferrous Sulfate Co; 170mg; Tablet; 100 Tablets
• Ferrous Sulfate Co; 170mg; Tablet; 56 Tablets
• Ferrous Sulfate Co; 170mg; Tablet; 84 Tablets
• Filgrastim; 30MU; Syringe, Prefilled; 1 Syringe, Pre-filled
• Filgrastim; 48MU; Syringe, Prefilled; 1 Syringe, Pre-filled
• Flucloxacillin; 250mg; Capsule; 100 Capsules
• Fluconazole; 200mg/100ml; Infusion (parenteral); 100 ml
• Fluconazole; 200mg; Tablet; 28 Tablets
• Fluconazole; 50mg/5ml; Suspension; 35 ml
• Fluconazole; 50mg; Tablet; 14 Tablets
• Fludarabine; 10mg; Tablet; 20 Tablets
• Fludarabine; 50mg; injection; 1 Injection
• Fluocinolone Acetonide; 0.025%; Ointment; 15 g
• Fluorouracil; 5%; Ointment; 20 g
• Fluoxetine; 20mg; Capsule; 100 Capsules
• Flupentixol; 20mg/ml; injection; 1 ml
• Fluticasone Propionate; 50mcg; Spray, Nasal; 120 Doses
• Folic Acid; 5mg; Tablet; 100 Tablets
• Formoterol; 12mcg; Inhaler; 120 Doses
• Fosfomycin; Granules; 1 Sachet (3g)
• Furosemide; 10mg/ml; Solution; 100 ml
• Furosemide; 20mg/2ml; injection; 2 ml
• Furosemide; 250mg/25ml; injection; 25 ml
• Furosemide; 40mg; Tablet; 112 Tablets
• Furosemide; 40mg; Tablet; 250 Tablets
• Furosemide; 500mg; Tablet; 100 Tablets
• Furosemide; 50mg/5ml; injection; 5 ml
• Ganciclovir; 500mg; injection; 1 Injection
• Gemcitabine; 1g; injection; 1 Injection
• Gemcitabine; 200mg; injection; 1 Injection
• Gentamicin; 20mg/2ml; injection; 2 ml
• Gentamicin; 80mg/2ml; injection; 2 ml
• Glibenclamide; 5mg; Tablet; 100 Tablets
• Glibenclamide; 5mg; Tablet; 84 Tablets
• Glucagon; 1mg; injection; 1 ml
• Glucometer; Medical device; 1 Device
• Glycerol; BP; Liquid; 500 ml
• Glycerol; 0.891ml; Suppository; 12 Suppositories
• Glycerol; 1.698ml; Suppository; 12 Suppositories
• Glyco Thymol Co; Mouthwash; 100 ml
• Glycopyrronium Bromide; 400mcg/2ml; injection; 2 ml
• Glycopyrronium Bromide; 50mcg; Inhaler; 30 Doses
• Goserelin; 10.8mg; Syringe, Prefilled; 1 Syringe, Pre-filled
• Goserelin; 3.6mg; Syringe, Prefilled; 1 Syringe, Pre-filled
• Granisetron; 1mg; injection; 1 Injection
• Granisetron; 3mg/3ml; injection; 3 ml
• Half Darrow With Glucose; 5%; Infusion (parenteral); 200 ml
• Half Darrow With Glucose; 5%; Infusion (parenteral); 500 ml
• Haloperidol; 1.5mg; Tablet; 100 Tablets
• Haloperidol; 5mg; Tablet; 100 Tablets
• Haloperidol; 5mg; Tablet; 28 Tablets
• Haloperidol; 5mg; Tablet; 56 Tablets
• Halothane; Liquid; 250 ml
• Heparin; 25000IU/5ml; injection; 5 ml
• Heparin; 5000IU/5ml; injection; 5 ml
• HUMAN COAGULATION CONCENTRATE COMPLEX: FACTOR VIII COMPLEX 1 000 IU INJECTION, UNIT CONTAINING - A HIGH SPECIFIC FACTOR VIII (FACTOR VIII: C) ACTIVITY - VON WILLEBRAND FACTOR (FACTOR
• HUMAN COAGULATION CONCENTRATE COMPLEX: FACTOR VIII COMPLEX 500 IU INJECTION, UNIT CONTAINING - A HIGH SPECIFIC FACTOR VIII (FACTOR VIII: C) ACTIVITY - VON WILLEBRAND FACTOR (FACTOR
• Human Coagulation Factor Concentrate: Activated Prothrombin Complex; 500IU; injection; 1 Injection
• Human Coagulation Factor Concentrate: Activated Prothrombin Complex; 1,000IU; injection; 1 Injection
• Human Coagulation Factor Concentrate: Factor Ix Complex; 500IU; injection; 1 Injection
• Human Coagulation Factor Concentrate: Factor Viia Complex; 100,000IU; injection; 1 Injection
• Human Coagulation Factor Concentrate: Factor Viia Complex; 250,000IU; injection; 1 Injection
• Human Coagulation Factor Concentrate: Factor Viia Complex; 50,000IU; injection; 1 Injection
• Human Coagulation Factor Concentrate: Factor Viii Complex; 1,000IU; injection; 1 Injection
• Human Coagulation Factor Concentrate: Factor Viii Complex; 300IU; injection; 1 Injection
• Human Coagulation Factor Concentrate: Factor Viii Complex; 500IU; injection; 1 Injection
• Hyaluronic Acid; 10mg/ml; Syringe, Prefilled; 0.4 ml
• Hyaluronic Acid; 10mg/ml; Syringe, Prefilled; 0.55 ml
• Hydralazine; 25mg; Tablet; 56 Tablets
• Hydralazine; 25mg; Tablet; 84 Tablets
• Hydrochlorothiazide; 12.5mg; Tablet; 28 Tablets
• Hydrocortisone; 1%; Cream; 20 g
• Hydrocortisone; 1%; Ointment; 25 g
• Hydrocortisone; 10mg; Tablet; 100 Tablets
• Hydroxypropylmethylcellulose; 3mg/ml; Drop, Eye; 20 ml
• Hydroxyurea; 500mg; Capsule; 100 Capsules
• Hyoscine butylbromide; 10mg; Tablet; 10 Tablets
• Hyoscine butylbromide; 20mg/ml; injection; 1 ml
• Hyoscine butylbromide; 5mg/5ml; Syrup; 100 ml
• Ibandronic acid; 6mg; injection; 6 ml
• Ibuprofen; 100mg/5ml; Suspension; 100 ml
• Ibuprofen; 400mg; Tablet; 100 Tablets
• Ibuprofen; 400mg; Tablet; 84 Tablets
• Ifosfamide; 1g; injection; 1 Injection
• Ifosfamide; 2g; injection; 1 Injection
• Ifosfamide; 500mg; injection; 1 Injection
• Imatinib; 100mg; Capsule; 60 Capsules
• Imatinib; 400mg; Capsule; 30 Capsules
• Imipenem, Cilastatin; 500mg, 500mg; injection; 1 Injection
• Immunoglobulin, Anti-D; 100mcg; injection; 2 ml
• Immunoglobulin, Hepatitis B; 100IU/2ml; injection; 1 Injection
• Immunoglobulin, Human, Normal; 12g; Infusion (parenteral); 1 Injection
• Immunoglobulin, Human, Normal; 16%; injection; 2 ml
• Immunoglobulin, Human, Normal; 16%; injection; 5 ml
• Immunoglobulin, Human, Normal; 1g; Infusion (parenteral); 1 Injection
• Immunoglobulin, Human, Normal; 3g; Infusion (parenteral); 1 Injection
• Immunoglobulin, Human, Normal; 6g; Infusion (parenteral); 1 Injection
• Immunoglobulin, Rabies; 150IU/ml; injection; 2 ml
• Indometacin; 25mg; Capsule; 100 Capsules
• Insulin, Biosynthetic, Human, Isophane; 100IU/ml; injection; 10 ml
• Insulin, Biosynthetic, Human, Isophane; 100IU/ml; pen, prefilled; 3 ml
• Insulin, Biosynthetic, Human, Biphasic 30/70; 100IU/ml; injection; 10 ml
• Insulin, Biosynthetic, Human, Biphasic 30/70; 100IU/ml; pen, prefilled; 3 ml
• Insulin, Biosynthetic, Human, Soluble; 100IU/ml; injection; 10 ml
• Insulin, Biosynthetic, Human, Soluble; 100IU/ml; pen, prefilled; 3 ml
• Interferon Beta-1a; 6MIU; injection; 1 Injection
• Interferon Beta-1b; 8MIU; injection; 1 Injection
• Iohexol; 300mg/ml; injection; 100 ml
• Iohexol; 300mg/ml; injection; 20 ml
• Iohexol; 300mg/ml; injection; 50 ml
• Iohexol; 350mg/ml; injection; 100 ml
• Iohexol; 350mg/ml; injection; 50 ml
• Iomeprol; 400mg/ml; injection; 100 ml
• Iopamidol; 370mg/ml; injection; 100 ml
• Iopamidol; 370mg/ml; injection; 50 ml
• Iopromide; 300mg/ml; injection; 50 ml
• Iopromide; 370mg/ml; injection; 100 ml
• Ipratropium Bromide; 20mcg; Inhaler; 200 Doses
• Ipratropium Bromide; 250mcg/2ml; solution, inhalation; 60 UDVs (2ml)
• Ipratropium Bromide; 500mcg/2ml; solution, inhalation; 60 UDVs (2ml)
• Irinotecan; 100mg/5ml; injection; 5 ml
• Irinotecan; 40mg/2ml; injection; 2 ml
• Iron (III) Hydroxide Dextran Complex; 100mg/2ml; injection; 2 ml
• Iron (III) Hydroxide Dextran Complex; 500mg/10ml; injection; 10 ml
• Iron Sucrose Co; 100mg/5ml; injection; 5 ml
• Isoflurane; Liquid; 250 ml
• Isosorbide Dinitrate; 10mg; Tablet; 84 Tablets
• Isosorbide Dinitrate; 5mg; Tablet; 50 Tablets
• Isosorbide mononitrate; 20mg; Tablet; 56 Tablets
• IUD, Copper; Implant; 1 Device
• IUD, Levonorgestrel; 52mg; Implant; 1 Device
• Ketamine; 1000mg/10ml; injection; 10 ml
• Ketamine; 200mg/20ml; injection; 20 ml
• Ketamine; 500mg/10ml; injection; 10 ml
• Ketoconazole; 200mg; Tablet; 30 Tablets
• Lactulose; 3.35g/5ml; Syrup; 150 ml
• Lactulose; 3.35g/5ml; Syrup; 500 ml
• Lamotrigine; 100mg; Tablet; 56 Tablets
• Lamotrigine; 200mg; Tablet; 56 Tablets
• Lamotrigine; 25mg; Tablet; 56 Tablets
• Lamotrigine; 50mg; Tablet; 56 Tablets
• Lanolin; 3%; ointment, eye; 3.5 g
• Leflunomide; 10mg; Tablet; 30 Tablets
• Leflunomide; 20mg; Tablet; 30 Tablets
• Letrozole; 2.5mg; Tablet; 28 Tablets
• Levodopa, Carbidopa; 100mg, 25mg; Tablet; 100 Tablets
• Levodopa, Carbidopa; 250mg, 25mg; Tablet; 100 Tablets
• Levofloxacin; 250mg; Tablet; 28 Tablets
• Levofloxacin; 500mg; Tablet; 28 Tablets
• Levonorgestrel, Ethinylestradiol, Triphasic; Tablet; 28 Tablets
• Levonorgestrel, Ethinylestradiol; 0.15mg, 0.03mg; Tablet (Monophasic); 28 Tablets
• Levonorgestrel; 0.03mg; Tablet; 28 Tablets
• Levonorgestrel; 1.5mg; Tablet; 1 Tablet
• Levothyroxine Sodium; 100mcg; Tablet; 30 Tablets
• Levothyroxine Sodium; 25mcg; Tablet; 28 Tablets
• Levothyroxine Sodium; 50mcg; Tablet; 100 Tablets
• Levothyroxine Sodium; 50mcg; Tablet; 30 Tablets
• Lidocaine, Epinephrine (Adrenaline); 2%, 12.5mg; dental cartridge; 1.8 ml
• Lidocaine; 1%; injection (not for iv use); 20 ml
• Lidocaine; 10%; injection; 5 ml
• Lidocaine; 2%; dental cartridge; 1.8 ml
• Lidocaine; 2%; injection (not for iv use); 20 ml
• Lidocaine; 2%; injection (not for iv use); 5 ml
• Linezolid; 100mg/5ml; Suspension; 150 ml
• Linezolid; 600mg/300ml; Infusion (parenteral); 300 ml
• Linezolid; 600mg; Tablet; 10 Tablets
• Liquid Paraffin; BP; Liquid; 200 ml
• Lopinavir, Ritonavir; 100mg, 25mg; Tablet; 60 Tablets
• Lopinavir, Ritonavir; 40mg, 10mg; Capsule; 120 Capsules
• Lopinavir, Ritonavir; 80mg/ml, 20mg/ml; Solution; 60 ml
• Lorazepam; 1mg; Tablet; 100 Tablets
• Lorazepam; 2.5mg; Tablet; 100 Tablets
• Losartan; 100mg; Tablet; 28 Tablets
• Losartan; 50mg; Tablet; 30 Tablets
• Lubricant, Jelly; Gel; 1 sachet (2.5g)
• Lubricant, Jelly; Gel; 50 g
• Lyophilised Plasma; Infusion (parenteral); 200 ml
• Lyophilised Plasma; Infusion (parenteral); 50 ml
• Magnesium Sulfate; 50%; injection; 2 ml
• Mannitol; 25%; injection; 50 ml
• Mannitol; 5%; Infusion (parenteral); 3 L
• Mebendazole; 100mg/5ml; Suspension; 30 ml
• Mebendazole; 100mg; Tablet; 6 Tablets
• Mebendazole; 500mg; Tablet; 1 Tablet
• Medroxyprogesterone; 10mg; Tablet; 30 Tablets
• Medroxyprogesterone; 150mg; injection; 1 Injection
• Medroxyprogesterone; 5mg; Tablet; 30 Tablets
• Melphalan; 2mg; Tablet; 25 Tablets
• Melphalan; 50mg; injection; 1 Injection
• Mercaptopurine; 50mg; Tablet; 25 Tablets
• Meropenem; 1g; injection; 30 ml
• Meropenem; 500mg; injection; 20 ml
• Mesalazine; 400mg; Tablet; 90 Tablets
• Mesna; 400mg; injection; 1 Injection
• Metformin; 500mg; Tablet; 112 Tablets
• Methadone; 2mg; Solution; 60 ml
• Methotrexate; 1g/10ml; injection; 10 ml
• Methotrexate; 2.5mg; Tablet; 100 Tablets
• Methotrexate; 50mg/2ml; injection; 2 ml
• Methotrexate; 5g/50ml; injection; 50 ml
• Methyl Salicylate; 10%; Ointment; 25 g
• Methyl Salicylate; 10%; Ointment; 25 g
• Methyldopa; 250mg; Tablet; 56 Tablets
• Methyldopa; 250mg; Tablet; 84 Tablets
• Methylphenidate; 10mg; Tablet; 30 Tablets
• Methylprednisolone Acetate; 40mg/ml; injection; 2 ml
• Methylprednisolone Acetate; 40mg/ml; injection; 5 ml
• Methylprednisolone Sodium Succinate; 500mg/8ml; injection; 8 ml
• Methylprednisolone; 40mg; injection; 1 Injection
• Metoclopramide; 10mg/2ml; injection; 2 ml
• Metoclopramide; 10mg; Tablet; 100 Tablets
• Metoclopramide; 5mg/5ml; Syrup; 100 ml
• Metronidazole; 200mg/5ml; Suspension; 100 ml
• Metronidazole; 200mg; Tablet; 21 Tablets
• Metronidazole; 200mg; Tablet; 21 Tablets
• Metronidazole; 200mg; Tablet; 250 Tablets
• Metronidazole; 200mg; Tablet; 28 Tablets
• Metronidazole; 400mg; Tablet; 100 Tablets
• Metronidazole; 400mg; Tablet; 21 Tablets
• Micafungin; 100mg; injection; 1 Injection
• Micafungin; 50mg; injection; 1 Injection
• Miconazole; 2%; Gel, Oral; 30 g
• Midazolam; 15mg; Tablet; 20 Tablets
• Midazolam; 50mg/10ml; injection; 10 ml
• Midazolam; 7.5mg; Tablet; 20 Tablets
• Mifepristone; 200mg; Tablet; 3 Tablets
• Minoxidil; 10mg; Tablet; 100 Tablets
• Minoxidil; 5mg; Tablet; 100 Tablets
• Misoprostol; 200mcg; Tablet; 60 Tablets
• Montelukast; 10mg; Tablet; 30 Tablets
• Montelukast; 4mg; Tablet, chew; 30 Tablets
• Montelukast; 5mg; Tablet; 30 Tablets
• Morphine; BP; Powder; 10 g
• Morphine; 10mg; Tablet, MR; 60 Tablets
• Morphine; 30mg; Tablet, MR; 60 Tablets
• Morphine; 60mg; Tablet, MR; 60 Tablets
• Moxifloxacin; 400mg/250ml; injection; 250 ml
• Moxifloxacin; 400mg; Tablet; 10 Tablets
• Moxifloxacin; 400mg; Tablet; 28 Tablets
• Moxifloxacin; 400mg; Tablet; 5 Tablets
• Multichamber TPN for Adults: High volume bag with electrolytes, Very high protein, Very high calorie for central line; Infusion (parenteral); 2 L
• Multichamber TPN for Adults: High volume bag with electrolytes: high protein, very high calorie for central line; Infusion (parenteral); 2 L
• Multichamber TPN for Adults: High volume bag with electrolytes: Moderate protein, high calorie through central line; Infusion (parenteral); 2 L
• Multichamber TPN for Adults: Low volume bag with electrolytes: low protein, moderate calorie through central line; Infusion (parenteral); 1.5 L
• Multichamber TPN for Adults: Moderate volume bag with electrolytes: Moderate protein, high calorie through central line; Infusion (parenteral); 1.5 L
• Multichamber TPN for Adults: Moderate volume bag without electrolytes: Moderate protein, high calorie through central line; Infusion (parenteral); 1 L
• Multichamber TPN for Adults: Very low volume weaning bag with electrolytes: very low protein, low calorie for central line; Infusion (parenteral); 1 L
• Mycophenolate Mofetil; 200mg/ml; Suspension; 175 ml
• Mycophenolate Mofetil; 250mg; Capsule; 100 Capsules
• Mycophenolate Mofetil; 500mg; Tablet; 50 Tablets
• Mycophenolic Acid; 180mg; Tablet; 120 Tablets
• Mycophenolic Acid; 360mg; Tablet; 120 Tablets
• Naloxone; 400mcg/ml; injection; 1 ml
• Naloxone; 40mcg/2ml; injection; 2 ml
• Neonatal Maintenance, Dextrose (Potassium Free); 33,5,33,100mmol; Infusion (parenteral); 200 ml
• Neonatal Maintenance, Dextrose; 20,15,2.5,0.5,21,2mmol, 10%; Infusion (parenteral); 200 ml
• Neostigmine; 2.5mg/ml; injection; 1 ml
• Nevirapine; 200mg; Tablet; 56 Tablets
• Nevirapine; 50mg/5ml; Suspension; 100 ml
• Nevirapine; 50mg/5ml; Suspension; 240 ml
• Nifedipine; 10mg; Capsule; 100 Capsules
• Nifedipine; 5mg; Capsule; 100 Capsules
• Nilotinib; 150mg; Capsule; 112 Capsules
• Nilotinib; 200mg; Capsule; 112 Capsules
• Nitrofurantoin; 100mg; Capsule; 50 Capsules
• Norethisterone Acetate; 5mg; Tablet; 30 Tablets
• Norethisterone Enanthate; 200mg/ml; injection; 1 ml
• Norgestrel, Ethinylestradiol; 0.5mg, 0.05mg; Tablet; 28 Tablets
• Nystatin; 100000IU/ml; Drop, Oral; 20 ml
• Octreotide; 0.05mg/ml; injection; 1 Injection
• Octreotide; 0.1mg/ml; injection; 1 Injection
• Olanzapine; 10mg; Tablet; 28 Tablets
• Olanzapine; 2.5mg; Tablet; 28 Tablets
• Olanzapine; 5mg; Tablet; 28 Tablets
• Olopatadine; 1mg/ml; Drop, Eye; 5 ml
• Ondansetron; 4mg/2ml; injection; 2 ml
• Ondansetron; 4mg; Tablet, dispersible; 10 Tablets
• Ondansetron; 8mg/4ml; injection; 4 ml
• Ondansetron; 8mg; Tablet; 10 Tablets
• Oral Rehydration; Powder; 1 Sachet
• Orphenadrine; 50mg; Tablet; 28 Tablets
• Orphenadrine; 50mg; Tablet; 56 Tablets
• Orphenadrine; 50mg; Tablet; 84 Tablets
• Oxaliplatin; 100mg; injection; 1 Injection
• Oxaliplatin; 50mg; injection; 1 Injection
• Oxazepam; 10mg; Tablet; 100 Tablets
• Oxazepam; 30mg; Tablet; 100 Tablets
• Oxybuprocaine; 0.4%; Drop, Eye; 3 ml
• Oxybutynin; 5mg; Tablet; 84 Tablets
• Oxymetazoline; 0.025%; Drop, Eye; 15 ml
• Oxymetazoline; 0.025%; Drop, Nasal; 10 ml
• Oxymetazoline; 0.05%; Drop, Nasal; 10 ml
• Oxymetazoline; 0.05%; Spray, Nasal; 15 ml
• Oxytocin; 5IU/ml; injection; 1 ml
• Paclitaxel; 100mg/16.7ml; injection; 16.7 ml
• Paclitaxel; 30mg/5ml; injection; 5 ml
• Pancreatin: Lipase, Amylase, Protease; 150mg; Capsule; 100 Capsules
• Pancreatin: Lipase, Amylase, Protease; 300mg; Capsule; 100 Capsules
• Pantoprazole; 40mg; injection; 1 Injection
• Paracetamol; 120mg/5ml; Syrup; 100 ml
• Paracetamol; 120mg/5ml; Syrup; 50 ml
• Paracetamol; 120mg/5ml; Syrup; 500 ml
• Pethidine; 25mg/ml; injection; 1 ml
• Phenobarbital, Vitamin B3 (Nicotinamide), Vitamin B6 (Pyridoxine), Vitamin B2 (Riboflavin), Vitamin B1 (Thiamine); 16mg/5ml, 10mg/5ml, 0.25mg/5ml, 1mg/5ml, 3mg/5ml; Syrup; 100 ml
• Phenobarbital; 30mg; Tablet; 28 Tablets
• Phenobarbital; 30mg; Tablet; 56 Tablets
• Phenobarbital; 30mg; Tablet; 84 Tablets
• Phenoxymethylpenicillin; 125mg/5ml; Suspension; 100 ml
• Phenoxymethylpenicillin; 250mg/5ml; Suspension; 100 ml
• Phenoxymethylpenicillin; 250mg; Tablet; 100 Tablets
• Phenoxymethylpenicillin; 250mg; Tablet; 40 Tablets
• Phenylephrine; 10mg/ml; injection; 1 ml
• Phenytoin; 100mg; Capsule; 100 Capsules
• Phenytoin; 100mg; Capsule; 84 Capsules
• Phenytoin; 250mg/5ml; injection; 5 ml
• Phospholipids, Total; 100mg/4ml; injection; 4 ml
• Phospholipids, Total; 200mg/8ml; injection; 8 ml
• Pilocarpine; 1%; Drop, Eye; 15 ml
• Piperacillin, Tazobactam; 4g, 500mg; injection; 30 ml
• Polystyrene Sulfonate; Powder; 454 g
• Potassium Chloride; BP; Powder; 500 g
• Potassium Chloride; 15%; injection; 10 ml
• Potassium Chloride; 600mg; Tablet; 100 Tablets
• Potassium Citrate; BP; Suspension; 200 ml
• Povidone Iodine; 1%; Liquid; 100 ml
• Povidone Iodine; 10%; Liquid; 1 L
• Povidone Iodine; 10%; Ointment; 25 g
• Povidone Iodine; 10%; Ointment; 500 g
• Povidone Iodine; 5%; Cream; 25 g
• Povidone Iodine; 5%; Cream; 500 g
• Pramipexole; 0.125mg; Tablet; 100 Tablets
• Pramipexole; 0.25mg; Tablet; 100 Tablets
• Pramipexole; 1mg; Tablet; 100 Tablets
• Praziquantel; 500mg; Tablet; 100 Tablets
• Prednisolone; 1%; Drop, Eye; 5 ml
• Prednisone; 5mg; Tablet; 100 Tablets
• Prednisone; 5mg; Tablet; 40 Tablets
• Prednisone; 5mg; Tablet; 56 Tablets
• Promethazine; 25mg/ml; injection; 1 ml
• Promethazine; 25mg; Tablet; 100 Tablets
• Promethazine; 50mg/2ml; injection; 2 ml
• Promethazine; 5mg/5ml; Elixir; 100 ml
• Propofol; 10mg/ml; injection; 20 ml
• Propofol; 10mg/ml; injection; 50 ml
• Propranolol; 10mg; Tablet; 250 Tablets
• Propranolol; 10mg; Tablet; 28 Tablets
• Propranolol; 10mg; Tablet; 50 Tablets
• Propranolol; 10mg; Tablet; 84 Tablets
• Propranolol; 40mg; Tablet; 250 Tablets
• Propranolol; 40mg; Tablet; 56 Tablets
• Propranolol; 40mg; Tablet; 84 Tablets
• Propylene Glycol; BP; Liquid; 2.5 L
• Pyrazinamide; 500mg; Tablet; 28 Tablets
• Pyrazinamide; 500mg; Tablet; 56 Tablets
• Pyrazinamide; 500mg; Tablet; 84 Tablets
• Pyridostigmine; 10mg; Tablet; 50 Tablets
• Pyridostigmine; 60mg; Tablet; 150 Tablets
• Quetiapine; 100mg; Tablet; 90 Tablets
• Quetiapine; 200mg; Tablet; 60 Tablets
• Quetiapine; 25mg; Tablet; 100 Tablets
• Quetiapine; 300mg; Tablet; 60 Tablets
• Quinine; 300mg/ml; injection; 1 ml
• Raltegravir; 100mg; Tablet; 56 Tablets
• Raltegravir; 25mg; Tablet; 56 Tablets
• Raltegravir; 400mg; Tablet; 56 Tablets
• Ranitidine; 50mg/2ml; injection; 2 ml
• Recombinant Anthihaemophilic Factor VIII; 1000IU; injection; 1 Dose
• Recombinant Anthihaemophilic Factor VIII; 250IU; injection; 1 Dose
• Recombinant Anthihaemophilic Factor VIII; 500IU; injection; 1 Dose
• Rifampicin, Isoniazid; 60mg, 60mg; Tablet; 28 Tablets
• Rifampicin, Isoniazid; 60mg, 60mg; Tablet; 56 Tablets
• Rifampicin, Isoniazid; 75mg, 50mg; Tablet; 84 Tablets
• Rifampicin, Pyrazinamide, Ethambutol, Isoniazid; 150mg, 400mg, 275mg, 75mg; Tablet; 28 Tablets
• Rifampicin, Pyrazinamide, Isoniazid; 75mg, 150mg, 50mg; Tablet; 84 Tablets
• Rifampicin; 150mg; Capsule; 100 Capsules
• Rifapentine; 150mg; Tablet; 24 Tablets
• Ringer Lactate; Infusion (parenteral); 1 L
• Ringer Lactate; Infusion (parenteral); 200 ml
• Risedronic Acid; 35mg; Tablet; 4 Tablets
• Risperidone; 0.5mg; Tablet; 30 Tablets
• Risperidone; 1mg/ml; Solution; 30 ml
• Risperidone; 1mg; Tablet; 30 Tablets
• Risperidone; 2mg; Tablet; 30 Tablets
• Risperidone; 3mg; Tablet; 30 Tablets
• Ritonavir; 100mg; Suspension; 30 Sachets
• Ritonavir; 100mg; Tablet; 56 Tablets
• Rituximab; 100mg/10ml; injection; 10 ml
• Rituximab; 500mg/50ml; injection; 50 ml
• Rocuronium Bromide; 50mg/5ml; injection; 5 ml
• Rosuvastatin; 10mg; Tablet; 30 Tablets
• Salbutamol, Ipratropium Bromide; 2.5mg/2.5ml, 0.5mg/2.5ml; solution, inhalation; 60 UDVs (2.5ml)
• Salmeterol, Fluticasone; 25mcg, 250mcg; Inhaler; 120 Doses
• Salmeterol, Fluticasone; 25mcg, 50mcg; Inhaler; 120 Doses
• Selenium Sulfide; 2.5%; Suspension; 50 ml
• Senna Glycosides; 13.5mg; Tablet; 20 Tablets
• Sevoflurane; BP; Liquid; 250 ml
• Silver Sulfadiazine; 1%; Cream; 250 g
• Silver Sulfadiazine; 1%; Cream; 50 g
• Silver Sulfadiazine; 1%; Cream; 500 g
• Sirolimus; 1mg; Tablet; 30 Tablets
• Sodium Bicarbonate; 4%; injection; 50 ml
• Sodium Bicarbonate; 4.2%; Infusion (parenteral); 200 ml
• Sodium Bicarbonate; 8.5%; injection; 50 ml
• Sodium Chloride, Dextrose; 0.2%, 5%; Infusion (parenteral); 200 ml
• Sodium Chloride, Dextrose; 0.45%, 5%; Infusion (parenteral); 1 L
• Sodium Chloride, Dextrose; 0.9%, 5%; Infusion (parenteral); 1 L
• Sodium Chloride, Dextrose; 0.9%, 5%; Infusion (parenteral); 200 ml
• Sodium Chloride; BP; Powder; 500 g
• Sodium Chloride; 0.45%; Infusion (parenteral); 1 L
• Sodium Chloride; 0.9%; Infusion (parenteral); 1 L
• Sodium Chloride; 0.9%; Infusion (parenteral); 100 ml
• Sodium Chloride; 0.9%; Infusion (parenteral); 200 ml
• Sodium Chloride; 0.9%; Infusion (parenteral); 200 ml
• Sodium Chloride; 0.9%; Infusion (parenteral); 50 ml
• Sodium Chloride; 0.9%; solution, irrigation, bag; 1 L
• Sodium Chloride; 0.9%; solution, irrigation, bag; 3 L
• Sodium Chloride; 0.9%; solution, irrigation, bottle; 1 L
• Sodium Chloride; 0.9%; solution, irrigation; 30 ml
• Sodium Chloride; 5%; Infusion (parenteral); 200 ml
• Sodium Phosphate, Sodium Acid Phosphate; Enema; 135 ml
• Sodium, Potassium, Calcium, Lactate; 131mmol, 5mmol, 108mmol, 29mmol; Infusion (parenteral) (Plasmalyte L); 1 L
• Sodium, Potassium, Calcium, Lactate; 35mmol/L, 12mmol/L, 47mmol/L, 50g/L; Infusion (parenteral) (Paediatric Maintenance); 500 ml
• Sodium, Potassium, Calcium, Lactate; 35mmol/L, 12mmol/L, 47mmol/L, 50g/L; Infusion (parenteral) (Paediatric Maintenance); 200 ml
• Soft Paraffin, White; BP; Ointment; 500 g
• Somatropin; 10mg/1.5ml; cartridge; 1.5 ml
• Somatropin; 5mg/1.5ml; cartridge; 1.5 ml
• Sorbitol; 70%; Solution; 500 ml
• Spacer With Mask For Adults; Medical device; 1 Device
• Spacer With Mask For Children; Medical device; 1 Device
• Spacer With Mask For Infants; Medical device; 1 Device
• Spironolactone; 100mg; Tablet; 60 Tablets
• Spironolactone; 25mg; Tablet; 200 Tablets
• Spironolactone; 25mg; Tablet; 56 Tablets
• Spironolactone; 25mg; Tablet; 84 Tablets
• Streptokinase; 1.5MIU; injection; 1 Injection
• Sulfamethoxazole, Trimethoprim; 400mg, 80mg; Tablet (Co-trimoxazole); 100 Tablets
• Sulfamethoxazole, Trimethoprim; 400mg/5ml, 80mg/5ml; injection; 5 ml
• Sulfasalazine; 500mg; Tablet; 100 Tablets
• Sunscreen; 30SPF; Cream; 150 ml
• Suxamethonium; 100mg/2ml; injection; 2 ml
• Syrup, Simplex; BP; Syrup; 2.5 L
• Tacrolimus; 0.5mg; Capsule; 30 Capsules
• Tacrolimus; 1mg; Capsule; 30 Capsules
• Tacrolimus; 5mg; Capsule; 30 Capsules
• Tamoxifen; 20mg; Tablet; 28 Tablets
• Tenofovir; 300mg; Tablet; 28 Tablets
• Teriflunomide; 14mg; Tablet; 28 Tablets
• Terizidone; 250mg; Capsule; 100 Capsules
• Test: Blood Glucose; test strip; 50 Test Strips
• Test: TB LAM AG; test kit; 25 Test Strips
• Test: Urine, Gluc., Prot., Bl., pH, Ket., Leuc., Nit., Bilir., Urob.; test kit; 100 Test Strips
• Tetracaine, Arnica, Salvia, Aluminium; Ointment; 10 g
• Thalidomide; 50mg; Capsule; 28 Capsules
• Theophylline; 200mg; Tablet, MR; 60 Tablets
• Theophylline; 300mg; Tablet, MR; 60 Tablets
• Timolol, Bimatoprost; 5mg/ml, 0.3mg/ml; Drop, Eye; 3 ml
• Timolol, Brimonidine; 5mg/ml, 2mg/ml; Drop, Eye; 5 ml
• Timolol, Travoprost; 5mg/ml, 40mcg/ml; Drop, Eye; 2.5 ml
• Tioguanine; 40mg; Tablet; 25 Tablets
• Topiramate; 100mg; Tablet; 60 Tablets
• Topiramate; 15mg; Capsule, Sprinkle; 60 Capsules
• Topiramate; 25mg; Tablet; 60 Tablets
• Topiramate; 50mg; Tablet; 60 Tablets
• TPN for Adults: High volume bag with electrolytes: high protein, high calorie for central line; Infusion (parenteral); 2 L
• TPN for Adults: Moderate volume bag without electrolytes: Moderate protein, high calorie For IV infusion through central line. Multichamber bag containing: Amino Acids: a minimum of histidine,
• TPN for Adults: Very low volume weaning bag with electrolytes: very low protein, low calorie for peripheral line; Infusion (parenteral); 1 L
• Trace Elements; injection; 10 ml
• Tramadol; 100mg/2ml; injection; 2 ml
• Tramadol; 100mg; Tablet, MR; 60 Tablets
• Tranexamic Acid; 500mg/5ml; injection; 5 ml
• Tranexamic Acid; 500mg; Tablet; 30 Tablets
• Trastuzumab; 440mg; injection; 1 Injection
• Tretinoin; 0.025%; Gel; 20 g
• Tretinoin; 10mg; Capsule; 100 Capsules
• Tropicamide; 1%; Drop, Eye; 15 ml
• Vaccine: BCG; Injection; 20 Doses
• Vaccine: Diphtheria, Tetanus; 2IU/20IU; injection; 10 Doses
• Vaccine: Diptheria, Haemophilus Influenzae B, Pertussis, Polio, Tetanus, Hepatitis B; Syringe, Prefilled; 1 Dose
• Vaccine: Hepatitis B Adult; 20mcg/ml; injection; 1 Dose
• Vaccine: Hepatitis B Peadiatric; 10mcg/0.5ml; injection; 10 Doses
• Vaccine: Human Papillomavirus, Bivalent; injection; 2 Doses
• Vaccine: Influenza; Syringe, Prefilled; 1 Dose
• Vaccine: Measles; injection; 10 Doses
• Vaccine: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate; injection; 1 Dose
• Vaccine: Pneumococcal, 23-Valent Polysaccharide; injection; 1 Dose
• Vaccine: Pneumococcal, Conjugated; Syringe, Prefilled; 1 Dose
• Vaccine: Rabies; injection; 1 Dose
• Vaccine: Rotavirus; Drop, Oral; 1 Dose
• Vaccine: Tetanus Toxoid; injection; 10 Doses
• Vaccine: Yellow Fever; injection; 1 Dose
• Valganciclovir; 450mg; Tablet; 60 Tablets
• Valproate Sodium; 100mg; Tablet, dispersible; 100 Tablets
• Valproic Acid, Valproate Sodium; 145mg, 333mg; Tablet, MR; 100 Tablets
• Valproic Acid, Valproate Sodium; 145mg, 333mg; Tablet, MR; 56 Tablets
• Valproic Acid, Valproate Sodium; 58mg, 133.2mg; Tablet, MR; 100 Tablets
• Valproic Acid, Valproate Sodium; 58mg, 133.2mg; Tablet, MR; 56 Tablets
• Valproic Acid, Valproate Sodium; 87mg, 199.8mg; Tablet, MR; 100 Tablets
• Valproic Acid, Valproate Sodium; 87mg, 199.8mg; Tablet, MR; 56 Tablets
• Valproic Acid; 200mg/5ml; Syrup; 300 ml
• Valproic Acid; 250mg/5ml; Syrup; 100 ml
• Vancomycin; 1g; injection; 1 Injection
• Vancomycin; 500mg; injection; 1 Injection
• Vecuronium; 4mg/2ml; injection; 2 ml
• Venlafaxine; 150mg; Tablet, MR; 30 Tablets
• Venlafaxine; 37.5mg; Tablet; 30 Tablets
• Venlafaxine; 75mg; Tablet; 30 Tablets
• Verapamil; 240mg; Tablet, MR; 30 Tablets
• Verapamil; 40mg; Tablet; 84 Tablets
• Vinblastine; 10mg/10ml; injection; 1 Injection
• Vincristine; 2mg/2ml; injection; 2 ml
• Vitamin A (Retinol); 100,000IU; Capsule; 50 Capsules
• Vitamin A (Retinol); 200,000IU; Capsule; 50 Capsules
• Vitamin A (Retinol); 50,000IU; Capsule; 50 Capsules
• Vitamin B1 (Thiamine); 100mg/ml; injection; 10 ml
• Vitamin B1 (Thiamine); 100mg; Tablet; 84 Tablets
• Vitamin B12 (Cyanocobalamin); 1mg/ml; injection; 1 ml
• Vitamin B3 (Nicotinamide); 100mg; Tablet; 28 Tablets
• Vitamin B3 (Nicotinamide); 100mg; Tablet; 84 Tablets
• Vitamin B6 (Pyridoxine); 25mg; Tablet; 100 Tablets
• Vitamin D (Alfacalcidol); 0.25mcg; Capsule; 30 Capsules
• Vitamin D (Alfacalcidol); 1mcg; Capsule; 30 Capsules
• Vitamin D2 (Ergocalciferol); 5,000IU/ml; Drop, Oral; 15 ml
• Vitamin D2 (Ergocalciferol); 50,000IU; Tablet; 100 Tablets
• Vitamin D3 (Calcitriol); 0.25mcg; Capsule; 30 Capsules
• Vitamin K1 (Phytomenadione); 10mg; injection; 1 ml
• Vitamin K1 (Phytomenadione); 2mg; injection; 0.2 ml
• Vitamin, Fat Soluble, Vitamin E; injection; 10 ml
• Vitamin, Multi; Drop, Oral; 25 ml
• Vitamin, Multi; injection; 10 ml
• Vitamin, Multi; Syrup; 100 ml
• Vitamin, Water Soluble; injection (for intravenous use in adults); 10 ml
• Warfarin; 5mg; Tablet; 100 Tablets
• Water For Injection; injection; 10 ml
• Water For Injection; injection; 20 ml
• Water For Irrigation; Liquid (Pour Water); 1 L
• Water For Irrigation; Liquid; 1 L
• Water For Irrigation; Liquid; 3 L
• Zidovudine, Lamivudine; 300mg, 150mg; Tablet; 56 Tablets
• Zidovudine, Lamivudine; 300mg, 150mg; Tablet; 56 Tablets
• Zidovudine; 100mg; Capsule; 100 Capsules
• Zidovudine; 300mg; Capsule; 56 Capsules
• Zidovudine; 50mg/5ml; Syrup; 200 ml
• Zinc Oxide, Castor Oil; Ointment; 25 g
• Zinc Sulfate; 10mg/5ml; Syrup; 150 ml
• Zinc Sulfate; 20mg; Tablet; 10 Tablets
• Zinc Sulfate; 20mg; Tablet; 100 Tablets
• Zuclopentixol Acetate; 50mg/ml; injection; 1 ml
• Zuclopentixol Decanoate; 200mg/ml; injection; 1 ml

END.

Reply:

a) The KwaZulu-Natal Department of Human Settlement has advised that all flood victims have been moved from mass care centres and municipal halls. The Department has identified 15 land parcels that are at various stages of planning to build houses for the flood victims.

Property Description	Ward No.	Region	Developmental stage
1.Erf 3213 Reservoir Hills	23	West	Detailed planning
2.Erf 1765 Shallcross Extension 1	17	West	Detailed planning
3.Erf 4519 Reservoir Hills	23	West	Detailed planning
4.Erf 165 Shallcross	17	West	Detailed planning
5.Erven 253-2589 Edgely (Ntshongweni)	7	West	Detailed planning
6.Erf 113 Burlington Heights	65	West	Detailed planning
7.Erf 4687 Kwandengezi A	TBC	West	Detailed planning
8. Portion 21 of Farm Uitkoms & Doornug No.852	5	West	Detailed planning
9.Rem of Ptn 97 of the Farm Klaarwater No.951	17	West	Detailed planning
10.Rem of Ptn 63 of Farm Langefontein No.5981	9	West	Detailed planning
11.Rem of Ptn 2139 Cotton Lands	58	West	Detailed planning
12.Erf 1615 Ntuzuma A	38	West	Detailed planning

b) The movement of flood victims from municipal halls commenced from October 2022 to 24 December 2022

c) The challenges experienced included the following;

1. Finding suitable land for development.
2. Undertaking feasibility studies.
3. Land development planning and approval.
4. Slow pace of constructing Temporary Residential Units (TRUs).
5. Business forums like Delangokubona, that have a negative impact on service delivery.
6. Theft of material on-site.
7. Councillors obstructing relocation by:

• (i) Refusing the import of communities into their wards,
• (ii) Refusing the relocation of flood victims outside their wards
• (iii) Communities not being accommodative to flood victims who are relocated to their neighbourhoods.

Reply:

Yes, I have been informed that there is one ambulance based in Keimoes, however, an ambulance that is based in Kakamas also responds to Keimoes when needed. It must be noted that these are remote areas with low population density and low call out rates.

END.

Reply:

a) The intervention measures are coordinated at local facility level, supported by the District and Provincial administration. During the NEHAWU led strike, the clinical leadership at each facility put in place mechanisms to reduce the impact, including some staff volunteering to work longer hours, some staff performing duties not normally allocated to them e.g. feeding of patients, cleaning the wards. This included a real-time system of diverting emergencies to health facilities that were not or were less severely affected by the strike activities.

The intervention measures also included the National Department of Health led by the Minister, Provincial Departments of Health led by the MEC’s and senior officials in providing support at facility level. The National Health Council also ensure that a coordinated strategy is developed and implemented to support local facility management including monitoring and managing the strike. In selected instances, assistance was sought and received from South African Military Health Services for the most hard hit hospitals.

b) So far, only six (6) deaths are alleged to be attributed to the strike. However, these are subject to ongoing investigation.

END.

Reply:

Yes, the Minister of Cooperative Governance and Traditional Affairs supported Ditsobotla Local Municipality (DLM) in accordance with section 154 of the Constitution by deploying, through the Municipal Infrastructure Support Agent (MISA), four professionally registered built environment practitioners that include two Civil Engineers to support DLM, together with other municipalities within Ngaka Modiri District Municipality (NMDM), in accordance with the District Development Model (DDM). These professionals provide technical support to DLM for infrastructure development throughout the project life cycle from inception, planning, design development, implementation, operations and maintenance that includes roads repairs and refurbishments. Furthermore, DLM was allocated R41 395 000 (R41,395 million) of the Municipal Infrastructure Grant (MIG) that is administered by the Department of Cooperative Governance (DCOG) in the 2022-23 financial year. The MISA deployed professionals provide DLM with both MIG programme support as well as respective MIG funded projects support. The MISA professionals are currently supporting DLM with the implementation of a MIG funded road network upgrading project of R 23 278 513.44 in Blydeville which is in Ward 4. The project is scheduled to be completed in the next financial year. The deployed MISA professionals are supporting DLM to prioritise and plan roads repair projects to be implemented by the North-West Province Department of Public Works and Roads (NWPDPWR) after the signing of a Memorandum of understanding (MOU) on 14 November 2022 between NWPDPWR and DLM. The MOU aims to assist DLM by NWPDPWR with repairing and maintenance of municipal roads. The MOU will be reviewed after a year.

Ditsobotla Local Municipality has been experiencing perennial governance and administration challenges resulting in its failure to fulfil its constitutional obligations including sustainable service delivery. The North-West Provincial Executive Council resultantly intervened by invoking Section 139 of the Constitution which is currently in place. DCOG is monitoring the provincial executive intervention. Section 139 (7) of the Constitution provides, among other things, that if the provincial executive does not adequately exercise the powers or perform the functions the national executive must then intervene.

End.

Reply:

As a result of the process and procedure that must be followed and finished before the final regulation can come into effect, the Department of Military Veterans is working tirelessly to ensure that the military veterans pensions benefit can be paid out, but there is no precise date as to when the military veterans' pension will be paid until all due processes are completed.

Reply:

1. The Chief of Logistics registered and approved the project to build a perimeter fence around the training area because it falls under his responsibility, but it was unable to be executed due to lack of funding.

2. The project will be carried out depending on the availability of funds after it was unable to be executed owing to financial restrictions.

3. The SANDF is currently not involved in any collaborative anti-poaching efforts in the area with other departments due to roles and functions as well as boundary management.